NAYA Biosciences (NAYA) 10-Q 14 Aug 24 2024 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2024	Aug. 14, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2024
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	001-39701
Entity Registrant Name	INVO Bioscience, Inc.
Entity Central Index Key	0001417926
Entity Tax Identification Number	20-4036208
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	5582 Broadcast Court
Entity Address, City or Town	Sarasota
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	34240
City Area Code	(978)
Local Phone Number	878-9505
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	INVO
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		3,906,072

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Current assets
Cash	$ 942,934	$ 232,424
Accounts receivable	257,210	140,550
Inventory	250,066	264,507
Prepaid expenses and other current assets	945,853	622,294
Total current assets	2,396,063	1,259,775
Property and equipment, net	441,365	826,418
Lease right of use	2,614,466	5,740,929
Intangible assets, net	3,684,681	4,093,431
Goodwill	5,878,986	5,878,986
Equity investments	844,198	916,248
Investment in NAYA	2,172,000	2,172,000
Total assets	18,031,759	20,887,787
Current liabilities
Accounts payable and accrued liabilities	2,378,099	2,330,381
Accrued compensation	646,838	722,251
Deferred revenue	416,745	408,769
Lease liability, current portion	237,030	397,554
Additional payments for acquisition, current portion	2,500,000	2,500,000
Other current liabilities	350,000	350,000
Total current liabilities	7,988,798	8,218,875
Notes payable, net of current portion	1,172,902	1,253,997
Lease liability, net of current portion	2,506,543	5,522,090
Additional payments for acquisition, net of current portion	5,000,000	5,000,000
Total liabilities	16,668,243	19,994,962
Stockholders’ equity
Common Stock, $.0001 par value; 50,000,000 shares authorized; 3,864,072 and 2,492,531 issued and outstanding as of June 30, 2024 and December 31, 2023, respectively	386	249
Additional paid-in capital	55,767,189	52,710,721
Accumulated deficit	(61,910,463)	(57,818,145)
Total stockholders’ equity	1,363,516	892,825
Total liabilities and stockholders’ equity	18,031,759	20,887,787
Series A Preferred Stock [Member]
Stockholders’ equity
Preferred Stock, value	1,506,404
Series B Preferred Stock [Member]
Stockholders’ equity
Preferred Stock, value	6,000,000	6,000,000
Nonrelated Party [Member]
Current liabilities
Notes payable – related parties, net	580,086	629,920
Related Party [Member]
Current liabilities
Notes payable – related parties, net	$ 880,000	$ 880,000

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2024	Dec. 31, 2023
Preferred stock, par value	$ 5
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	3,864,072	2,492,531
Common stock, shares outstanding	3,864,072	2,492,531
Series A Preferred Stock [Member]
Preferred stock, par value	$ 5	$ 5
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	301,280	0
Preferred stock, shares outstanding	301,280	0
Series B Preferred Stock [Member]
Preferred stock, par value	$ 5	$ 5
Preferred stock, shares authorized	1,200,000	1,200,000
Preferred stock, shares issued	1,200,000	1,200,000
Preferred stock, shares outstanding	1,200,000	1,200,000

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenue:
Total revenue	$ 1,836,597	$ 315,902	$ 3,412,883	$ 663,927
Operating expenses
Cost of revenue	861,648	235,714	1,711,882	466,719
Selling, general and administrative expenses	2,647,524	2,042,609	4,088,110	4,373,443
Research and development expenses		83,850	4,880	157,370
Depreciation and amortization	230,338	19,705	457,298	38,792
Total operating expenses	3,739,510	2,381,879	6,262,170	5,036,324
Loss from operations	(1,902,913)	(2,065,977)	(2,849,287)	(4,372,397)
Other income (expense):
Gain (loss) from equity method joint ventures	17,846	3,788	17,950	(23,947)
Gain (loss) on disposal of fixed assets	50,000		(511,663)
Gain on lease termination			94,551
Loss on debt extinguishment	(40,491)		(40,491)
Interest expense	(369,612)	(175,192)	(550,907)	(391,781)
Foreign currency exchange loss		(265)		(400)
Total other income (expense)	(342,257)	(171,669)	(990,560)	(416,128)
Net loss before income taxes	(2,245,170)	(2,237,646)	(3,839,847)	(4,788,525)
Income taxes		2,865	1,836	2,865
Net loss	$ (2,245,170)	$ (2,240,511)	$ (3,841,683)	$ (4,791,390)
Net loss per common share:
Basic	$ (0.62)	$ (3.06)	$ (1.25)	$ (7.07)
Diluted	$ (0.62)	$ (3.06)	$ (1.25)	$ (7.07)
Weighted average number of common shares outstanding:
Basic	3,609,812	732,255	3,072,877	677,684
Diluted	3,609,812	732,255	3,072,877	677,684
Clinic Revenue [Member]
Revenue:
Total revenue	$ 1,807,921	$ 254,364	$ 3,345,120	$ 551,745
Product [Member]
Revenue:
Total revenue	$ 28,676	$ 61,538	$ 67,763	$ 112,182

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Common Stock [Member]	Preferred Stock [Member] Series A Preferred Stock [Member]	Preferred Stock [Member] Series B Preferred Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2022	$ 61			$ 48,805,860	$ (49,783,533)	$ (977,612)
Balance, shares at Dec. 31, 2022	608,611
Common stock issued to directors and/or employees				46,503		46,503
Common stock issued to directors and/or employees, shares	3,490
Common stock issued for services	$ 1			149,899		149,900
Common stock issued for services, shares	13,000
Proceeds from the sale of common stock, net of fees and expenses	$ 7			2,708,635		2,708,642
Proceeds from the sale of common stock, net of fees and expenses, shares	69,000
Common stock issued with notes payable				56,313		56,313
Common stock issued with notes payable, shares	4,167
Options exercised for cash				2,376		2,376
Options exercised for cash, shares	297
Stock options issued to directors and employees as compensation				325,834		325,834
Warrants issued with notes payable				327,389		327,389
Net loss					(2,550,879)	(2,550,879)
Balance at Mar. 31, 2023	$ 69			52,422,809	(52,334,412)	88,466
Balance, shares at Mar. 31, 2023	698,565
Balance at Dec. 31, 2022	$ 61			48,805,860	(49,783,533)	(977,612)
Balance, shares at Dec. 31, 2022	608,611
Net loss						(4,791,390)
Balance at Jun. 30, 2023	$ 83			52,869,346	(54,574,923)	(1,705,494)
Balance, shares at Jun. 30, 2023	826,886
Balance at Mar. 31, 2023	$ 69			52,422,809	(52,334,412)	88,466
Balance, shares at Mar. 31, 2023	698,565
Common stock issued to directors and/or employees				5,062		5,062
Common stock issued to directors and/or employees, shares	504
Common stock issued for services	$ 2			94,274		94,276
Common stock issued for services, shares	12,817
Proceeds from the sale of common stock, net of fees and expenses	$ 12			20,285		20,297
Proceeds from the sale of common stock, net of fees and expenses, shares	115,000
Stock options issued to directors and employees as compensation				326,916		326,916
Net loss					(2,240,511)	(2,240,511)
Balance at Jun. 30, 2023	$ 83			52,869,346	(54,574,923)	(1,705,494)
Balance, shares at Jun. 30, 2023	826,886
Balance at Dec. 31, 2023	$ 249		$ 6,000,000	52,710,721	(57,818,145)	892,825
Balance, shares at Dec. 31, 2023	2,492,531		1,200,000
Common stock issued to directors and/or employees				92		92
Common stock issued for services	$ 13			142,437		142,450
Common stock issued for services, shares	125,500
Stock options issued to directors and employees as compensation				71,301		71,301
Net loss					(1,596,513)	(1,596,513)
Preferred stock issued		$ 500,000				500,000
Preferred stock issued, shares		100,000
Balance at Mar. 31, 2024	$ 262	$ 500,000	$ 6,000,000	52,924,551	(59,414,658)	10,155
Balance, shares at Mar. 31, 2024	2,618,031	100,000	1,200,000
Balance at Dec. 31, 2023	$ 249		$ 6,000,000	52,710,721	(57,818,145)	$ 892,825
Balance, shares at Dec. 31, 2023	2,492,531		1,200,000
Options exercised for cash, shares
Net loss						$ (3,841,683)
Balance at Jun. 30, 2024	$ 386	$ 1,506,404	$ 6,000,000	55,767,189	(61,910,463)	1,363,516
Balance, shares at Jun. 30, 2024	3,864,072	301,280	1,200,000
Balance at Mar. 31, 2024	$ 262	$ 500,000	$ 6,000,000	52,924,551	(59,414,658)	10,155
Balance, shares at Mar. 31, 2024	2,618,031	100,000	1,200,000
Common stock issued to directors and/or employees				61		61
Common stock issued for services	$ 6			59,992		59,998
Common stock issued for services, shares	69,155
Proceeds from the sale of common stock, net of fees and expenses	$ 26			165,105		165,131
Proceeds from the sale of common stock, net of fees and expenses, shares	260,000
Stock options issued to directors and employees as compensation				69,035		69,035
Warrants issued with notes payable				188,755		188,755
Net loss					(2,245,170)	(2,245,170)
Preferred stock issued		$ 1,006,404				1,006,404
Preferred stock issued, shares		201,280
Convertible note modification/extinguishment				40,491		40,491
Warrants issued for services				971,012		971,012
Debt conversion	$ 11			197,022		197,033
Debt conversion, shares	109,886
Warrant exercise	$ 81			900,530		900,611
Warrant exercise, shares	807,000
Deemed dividend				250,635	(250,635)
Balance at Jun. 30, 2024	$ 386	$ 1,506,404	$ 6,000,000	$ 55,767,189	$ (61,910,463)	$ 1,363,516
Balance, shares at Jun. 30, 2024	3,864,072	301,280	1,200,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash flows from operating activities:
Net loss	$ (3,841,683)	$ (4,791,390)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock compensation issued for services	1,173,460	244,176
Stock compensation issued to directors and employees	153	51,565
Fair value of stock options issued to employees	140,336	652,750
Non-cash compensation for services	90,000	90,000
Amortization of discount on notes payable	349,010	301,098
Loss (gain) from equity method investment	(17,950)	23,947
Loss from debt extinguishment	40,491
Loss from disposal of assets	511,663
Gain on lease termination	(94,551)
Depreciation and amortization	457,298	38,792
Changes in assets and liabilities:
Accounts receivable	(116,660)	2,241
Inventory	14,441	(16,416)
Prepaid expenses and other current assets	(469,479)	(184,513)
Accounts payable and accrued expenses	35,435	432,654
Accrued compensation	(75,413)	256,158
Deferred revenue	7,976	41,311
Leasehold liability	10,080	1,829
Accrued interest	69,179	62,938
Net cash used in operating activities	(1,716,214)	(2,792,860)
Cash from investing activities:
Payments to acquire property, plant, and equipment	(104,829)	(261,505)
Proceeds from sale of fixed assets	75,590
Investment in joint ventures		(8,447)
Net cash used in investing activities	(29,239)	(269,952)
Cash from financing activities:
Proceeds from the sale of notes payable	442,500	714,000
Proceeds from the sale of common stock, net of offering costs	165,131	2,728,938
Proceeds from sale of preferred stock	1,506,404
Proceeds from warrant exercise	900,611
Proceeds from option exercise		2,375
Principal payments on note payable	(558,683)	(360,151)
Net cash provided by financing activities	2,455,963	3,085,162
Increase (decrease) in cash and cash equivalents	710,510	22,350
Cash and cash equivalents at beginning of period	232,424	90,135
Cash and cash equivalents at end of period	942,934	112,485
Supplemental disclosure of cash flow information:
Interest	108,513	5,720
Noncash activities:
Common stock issued upon conversion notes payable and accrued interest	197,033
Fair value of warrants issued with debt	188,755	327,390
Deemed dividend	250,635
Fair value of shares issued upon the conversion of debt		197,033
Initial ROU asset and lease liability		$ 2,312,892

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023
Pay vs Performance Disclosure [Table]
Net Income (Loss)	$ (2,245,170)	$ (1,596,513)	$ (2,240,511)	$ (2,550,879)	$ (3,841,683)	$ (4,791,390)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Jun. 30, 2024
Insider Trading Arrangements [Line Items]
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Rule 10b5-1 Arrangement Modified	false
Non-Rule 10b5-1 Arrangement Modified	false

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 1 – Summary of Significant Accounting Policies Description of Business INVO Bioscience, Inc. (“INVO” or the “Company”) is a healthcare services company dedicated to expanding access to fertility care around the world. The Company’s commercial strategy is primarily focused on operating fertility-focused clinics, which include the opening of “INVO Centers” dedicated primarily to offering the intravaginal culture (“IVC”) procedure enabled by its INVOcell® medical device (“INVOcell”) and the acquisition of US-based, profitable in vitro fertilization (“IVF”) clinics. The Company has two operational INVO Centers in the United States and completed its first IVF clinic acquisition in August 2023. The Company also continues to engage in the sale and distribution of its INVOcell technology solution into existing independently owned and operated fertility clinics. Basis of Presentation The accompanying consolidated financial statements present on a consolidated basis the accounts of the Company and its wholly owned subsidiaries and controlled affiliates. The Company presents noncontrolling interest within the equity section of its consolidated balance sheets and the amount of consolidated net income (loss) that is attributable to the Company and to the noncontrolling interest in its consolidated statement of operations. All significant intercompany accounts and transactions have been eliminated in consolidation. The Company uses the equity method of accounting when it owns an interest in an entity whereby it can exert significant influence over but cannot control the entity’s operations. The preparation of the Company’s consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. The Company considers events or transactions that have occurred after the consolidated balance sheet date of June 30, 2024, but prior to the filing of the consolidated financial statements with the SEC in this Quarterly Report on Form 10-Q, to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure, as applicable. Subsequent events have been evaluated through the date of the filing of this Quarterly Report on Form 10-Q. Reclassifications Certain amounts in the consolidated financial statements for the prior year have been reclassified to conform to the current year presentation. These reclassifications had no impact on net earnings, financial position, or cash flows. Business Segments The Company operates in one Business Acquisitions The Company accounts for all business acquisitions at fair value and expenses acquisition costs as they are incurred. Any identifiable assets acquired and liabilities assumed are recognized and measured at their respective fair values on the acquisition date. If information about facts and circumstances existing as of the acquisition date is incomplete at the end of the reporting period in which a business acquisition occurs, the Company will report provisional amounts for the items for which the accounting is incomplete. The measurement period ends once the Company receives sufficient information to finalize the fair values; however, the period will not exceed one year from the acquisition date. Any adjustments to provisional amounts that are identified during the measurement period are recognized in the reporting period in which the adjustment amounts are determined. Variable Interest Entities The Company’s consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries, and variable interest entities (“VIE”), where the Company is the primary beneficiary under the provisions of ASC 810, Consolidation (“ASC 810”). A VIE must be consolidated by its primary beneficiary when, along with its affiliates and agents, the primary beneficiary has both (i) the power to direct the activities that most significantly impact the VIE’s economic performance, and (ii) the obligation to absorb losses or the right to receive the benefits of the VIE that could potentially be significant to the VIE. The Company reconsiders whether an entity is still a VIE only upon certain triggering events and continually assesses its consolidated VIEs to determine if it continues to be the primary beneficiary. See “Note 3 – Variable Interest Entities” for additional information on the Company’s VIEs. Equity Method Investments Investments in unconsolidated affiliates, over which the Company exerts significant influence but does not control or otherwise consolidate, are accounted for using the equity method. Equity method investments are initially recorded at cost. These investments are included in investment in joint ventures in the accompanying consolidated balance sheets. The Company’s share of the profits and losses from these investments is reported in loss from equity method joint venture in the accompanying consolidated statements of operations. The Company monitors its investments for other-than-temporary impairment by considering factors such as current economic and market conditions and the operating performance of the investees and records reductions in carrying values when necessary. Use of Estimates In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates. Cash and Cash Equivalents For financial statement presentation purposes, the Company considers time deposits, certificates of deposit, and all highly liquid investments with original maturities of three months or less to be cash and cash equivalents. At times, cash and cash equivalents balances exceed amounts insured by the Federal Deposit Insurance Corporation. Inventory Inventories consist of raw materials, work in process and finished goods and are stated at the lower of cost or net realizable value, using the first-in, first-out method as a cost flow method. Property and Equipment The Company records property and equipment at cost. Property and equipment are depreciated using the straight-line method over the estimated economic lives of the assets, which are from 3 10 Long- Lived Assets Long-lived assets and certain identifiable assets related to those assets are periodically reviewed for impairment whenever circumstances and situations change such that there is an indication that the carrying amounts may not be recoverable. If the non-discounted future cash flows of the asset are less than their carrying amount, their carrying amounts are reduced to fair value and an impairment loss recognized. There was no Fair Value of Financial Instruments ASC 825-10-50, “Disclosures about Fair Value of Financial Instruments,” requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. Effective January 1, 2008, the Company adopted ASC 820-10, “Fair Value Measurements”, which provides a framework for measuring fair value under GAAP. ASC 820-10 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 requires that valuation techniques maximize the use of observable inputs and minimize the use of unobservable inputs. Income Taxes The Company is subject to income taxes in the United States and its domestic tax liabilities are subject to the allocation of expenses in multiple state jurisdictions. The Company uses the asset and liability method to account for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The recoverability of deferred tax assets is evaluated by assessing the adequacy of future expected taxable income from all sources, including taxable income in prior carryback years, reversal of taxable temporary differences, forecasted operating earnings, and available tax planning strategies. To the extent the Company does not consider it more-likely-than-not that a deferred tax asset will be recovered, a valuation allowance is established. Concentration of Credit Risk Cash includes amounts deposited in financial institutions in excess of insurable Federal Deposit Insurance Corporation (“FDIC”) limits. As of June 30, 2024, the Company had cash balances in excess of FDIC limits. Revenue Recognition The Company recognizes revenue on arrangements in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”). The core principle of ASC 606 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services ASC 606 requires companies to assess their contracts to determine the timing and amount of revenue to recognize under the new revenue standard. The model has a five-step approach: 1. Identify the contract with the customer. 2. Identify the performance obligations in the contract. 3. Determine the total transaction price. 4. Allocate the total transaction price to each performance obligation in the contract. 5. Recognize as revenue when (or as) each performance obligation is satisfied. Revenue generated from the sale of INVOcell is typically recognized at the time the product is shipped, at which time the title passes to the customer, and there are no further performance obligations. Revenue generated from clinical and lab services related at the Company’s affiliated INVO Centers is typically recognized at the time the service is performed. Stock Based Compensation The Company accounts for stock-based compensation under the provisions of Accounting Standards Codification (“ASC”) subtopic 718-10, Compensation (“ASC 718-10”). This statement requires the Company to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized over the period in which the employee is required to provide service or based on performance goals in exchange for the award, which is usually the vesting period. Loss Per Share Basic loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding. Diluted earnings per share are computed similarly to basic earnings per share except that the denominator is increased to include potentially dilutive securities. The Company’s diluted loss per share is the same as the basic loss per share for the three months ended June 30, 2024, and 2023, as the inclusion of any potential shares would have had an anti-dilutive effect due to the Company generating a loss. Schedule of Earnings Per Share Basic and Diluted 2024 2023 2024 2023 Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Net loss (numerator) $ (2,245,170 ) (2,240,511 ) (3,841,683 ) (4,791,390 ) Basic and diluted weighted-average number of common shares outstanding (denominator) 3,609,812 732,255 3,072,877 677,684 Basic and diluted net loss per common share (0.62 ) (3.06 ) (1.25 ) (7.07 ) The Company has excluded the following dilutive securities from the calculation of fully diluted shares outstanding because the result would have been anti-dilutive: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share 2024 2023 As of June 30, 2024 2023 Options 97,992 121,255 Convertible notes and interest 532,289 55,120 Preferred stock 1,884,727 - Warrants and unit purchase options 4,131,081 348,151 Total 6,646,089 524,526 Recently Adopted Accounting Pronouncements The Company has reviewed all recently issued, but not yet effective, accounting pronouncements, and does not believe the future adoption of any such pronouncements will have a material impact on its financial condition or the results of its operations.

Liquidity

Liquidity	6 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity	Note 2 – Liquidity Historically, the Company has funded its cash and liquidity needs primarily through revenue collection and debt and equity financings. For the six months ended June 30, 2024, and 2023, the Company incurred a net loss of approximately $ 3.8 4.8 61.9 2.6 1.4 The Company has been dependent on raising capital from debt and equity financings to meet its needs for cash used in operating and investing activities. During the first six months of 2024, the Company received $ 1.5 million from the sale of preferred stock, $ 0.9 million from the exercise of warrants, $ 0.4 0.2 Although the Company’s audited consolidated financial statements for the year ended December 31, 2023 were prepared under the assumption that it would continue operations as a going concern, the report of the Company’s independent registered public accounting firm that accompanies the Company’s financial statements for the year ended December 31, 2023 contains a going concern qualification in which such firm expressed substantial doubt about the Company’s ability to continue as a going concern, based on the financial statements at that time. Specifically, as noted above, the Company has incurred significant operating losses, and the Company expects to continue to incur significant expenses and operating losses as it continues to ramp up the commercialization of INVOcell and develop new INVO Centers. These prior losses and expected future losses have had, and will continue to have, an adverse effect on the Company’s financial condition. If the Company cannot continue as a going concern, its stockholders would likely lose most or all of their investment in the Company.

Business Combinations

Business Combinations	6 Months Ended
	Jun. 30, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]
Business Combinations	Note 3 – Business Combinations Wisconsin Fertility Institute On August 10, 2023, INVO, through Wood Violet Fertility LLC, a Delaware limited liability company (“Wood Violet”) and wholly owned subsidiary of INVO Centers LLC (“INVO CTR”), a Delaware company wholly-owned by INVO, consummated its acquisition of the Wisconsin Fertility Institute (“WFI”) for a combined purchase price of $ 10,000,000 2,500,000 2,150,000 350,000 528,756 2,500,000 125.00 181.80 285.80 WFI was comprised of (a) a medical practice, Wisconsin Fertility and Reproductive Surgery Associates, S.C., a Wisconsin professional service corporation d/b/a Wisconsin Fertility Institute (“WFRSA”), and (b) a laboratory services company, Fertility Labs of Wisconsin, LLC, a Wisconsin limited liability company (“FLOW”). WFRSA owned, operated, and managed WFI’s fertility practice that provided direct treatment to patients focused on fertility, gynecology, and obstetrics care and surgical procedures, and employed physicians and other healthcare providers to deliver such services and procedures. FLOW provided WFRSA with related laboratory services. INVO purchased the non-medical assets of WFRSA and one hundred percent of FLOW’s membership interests through Wood Violet. Concurrently, Wood Violet and WFRSA entered into a management services agreement pursuant to which WFRSA outsourced all its non-medical activities to Wood Violet. As a result, post-closing, WFI is comprised of (a) WFRSA, which only employs physicians to provide medical services, and (b) Wood Violet, which employs all other clinic personnel and provides all non-medical services, including laboratory services. FLOW is no longer operational as its operations were absorbed by Wood Violet. The Company’s consolidated financial statements for the six months ended June 30, 2024 include WFI’s results of operations. The Company’s condensed consolidated financial statements reflect the final purchase accounting adjustments in accordance with ASC 805 “Business Combinations”, whereby the purchase price was allocated to the assets acquired and liabilities assumed based upon their estimated fair values on the acquisition date. The following allocation of the purchase price is as follows: Schedule of Allocation of Purchase Price Consideration given: Cash 2,150,000 Holdback 350,000 Additional payments 7,500,000 Business acquisition cost 10,000,000 Assets and liabilities acquired: FLOW intercompany receivable 528,756 Accounts receivable 214,972 Property and equipment, net 25,292 Other current assets 56,274 Tradename 253,000 Noncompetition agreement 3,961,000 Goodwill 5,878,986 Deferred revenue (389,524 ) WFRSA intercompany note (528,756 ) Total assets and liabilities acquired 10,000,000

Variable Interest Entities

Variable Interest Entities	6 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Variable Interest Entities	Note 4 – Variable Interest Entities Consolidated VIEs Bloom INVO, LLC On June 28, 2021, INVO CTR entered into a limited liability company agreement (the “Bloom Agreement”) with Bloom Fertility, LLC (“Bloom”) to establish a joint venture entity, formed as “Bloom INVO LLC” (the “Georgia JV”), for the purposes of commercializing INVOcell, and the related IVC procedure, through the establishment of an INVO Center in the Atlanta, Georgia metropolitan area (the “Atlanta Clinic”). In consideration for INVO’s commitment to contribute up to $ 800,000 800 1,200,000 1,200 The responsibilities of Bloom include providing all medical services required for the operation of the Atlanta Clinic. The responsibilities of INVO CTR include providing certain funding to the Georgia JV, lab services quality management, and providing access to and being the exclusive provider of the INVOcell to the Georgia JV. INVO CTR also performs all required, industry specific compliance and accreditation functions, and product documentation for product registration. The Bloom Agreement provides Bloom with a “profits interest” in the Georgia JV and, in connection with such profits interest, states that profits and losses be allocated to its members based on a hypothetical liquidation of the Georgia JV. In such a scenario, liquidation proceeds would be distributed in the following order: (a) to INVO CTR until the difference between its capital contributions and distributions equals $ 0 150% The Atlanta Clinic opened to patients on September 7, 2021. The Company determined the Georgia JV is a VIE, and that the Company is its primary beneficiary because the Company has an obligation to absorb losses that are potentially significant and the Company controls the majority of the activities that impact the Georgia JV’s economic performance, specifically control of the INVOcell and lab services quality management. As a result, the Company consolidated the Georgia JV’s results with its own. As of June 30, 2024, the Company invested $ 0.9 0.5 47 0.1 0 Unconsolidated VIEs HRCFG INVO, LLC On March 10, 2021, INVO CTR entered into a limited liability company agreement with HRCFG, LLC (“HRCFG”) to establish a joint venture, formed as HRCFG INVO, LLC (the “Alabama JV”), for the purpose of commercializing INVOcell, and the related IVC procedure, through the establishment of an INVO Center in Birmingham, Alabama (the “Birmingham Clinic”). The Company also provides certain funding to the Alabama JV. INVO CTR and HRSCGF party owns 50% The Birmingham clinic opened to patients on August 9, 2021. The Company determined the Alabama JV is a VIE, and that there is no primary beneficiary. As a result, the Company uses the equity method to account for its interest in the Alabama JV. As of June 30, 2024, the Company invested $ 1.3 36 18 2 805 Positib Fertility, S.A. de C.V. On September 24, 2020, INVO CTR entered into a Pre-Incorporation and Shareholders Agreement with Francisco Arredondo, MD PLLC (“Arredondo”) and Security Health LLC, a Texas limited liability company (“Ramirez”, and together with INVO CTR and Arredondo, the “Shareholders”) to establish a joint venture, formed as Positib Fertility, S.A. de C.V. (the “Mexico JV”), under which the Shareholders sought to commercialize INVOcell and the related IVC procedure and to offer related medical treatments in Mexico through the establishment of an INVO Center in Monterrey, Mexico (the “Monterrey Clinic”). Each Shareholder owns one-third of the Mexico JV. The Monterrey Clinic opened to patients on November 1, 2021. The Company determined the Mexico JV is a VIE, and that there is no primary beneficiary. As a result, the Company uses the equity method to account for its interest in the Mexico JV. During the fourth quarter of 2023, our Mexico JV partner informed the Company that the primary physician onsite had resigned. The Company elected to impair the investment at year end 2023 in this JV due to the uncertainty and possibility that the Mexico JV may offer reduced services or suspend operations. The total impairment for 2023 was approximately $ 0.09 0 The following table summarizes our investments in unconsolidated VIEs: Schedule of Investments in Unconsolidated Variable Interest Entities Carrying Value as of Location Percentage June 30, December 31, 2023 HRCFG INVO, LLC Alabama, United States 50 % $ 844,198 916,248 Positib Fertility, S.A. de C.V. Mexico 33 % - - Total investment in unconsolidated VIEs $ 844,198 916,248 Earnings from investments in unconsolidated VIEs were as follows: Schedule of Earnings from Investments in Unconsolidated Variable Interest Entities 2024 2023 2024 2023 Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 HRCFG INVO, LLC $ 17,846 $ 19,474 $ 17,950 $ 805 Positib Fertility, S.A. de C.V. - (15,686 ) - (24,752 ) Total earnings (loss) from unconsolidated VIEs 17,846 3,788 17,950 (23,947 ) The following tables summarize the combined unaudited financial information of our unconsolidated VIEs: Schedule of Financial Information of Investments in Unconsolidated Variable Interest Entities 2024 2023 2024 2023 Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Statements of operations: Operating revenue $ 333,308 $ 458,069 $ 665,622 $ 807,396 Operating expenses (297,616 ) (466,184 ) (629,722 ) (880,050 ) Net profit (loss) 35,692 (8,115 ) 35,900 (72,654 ) June 30, 2024 December 31, 2023 Balance sheets: Current assets $ 286,582 288,369 Long-term assets 991,387 1,026,873 Current liabilities (517,415 ) (510,091 ) Long-term liabilities (123,060 ) (123,060 ) Net assets $ 637,494 682,091

Agreements and Transactions wit

Agreements and Transactions with VIE’s	6 Months Ended
	Jun. 30, 2024
Agreements And Transactions With Vies
Agreements and Transactions with VIE’s	Note 5 – Agreements and Transactions with VIE’s The Company sells INVOcells to its consolidated and unconsolidated VIEs and anticipates continuing to do so in the ordinary course of business. All intercompany transactions with consolidated entities are eliminated in the Company’s consolidated financial statements. Pursuant to ASC 323-10-35-8, the Company eliminates any sales to an unconsolidated VIE for INVOcell inventory that the VIE still has remaining on the books at period end. The following table summarizes the Company’s transactions with VIEs: Summary of Transaction with Variable Interest Entities 2024 2023 2024 2023 Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Bloom INVO, LLC INVOcell revenue $ 15,000 $ 6,000 $ 25,500 $ 10,500 Unconsolidated VIEs INVOcell revenue $ - $ 6,750 $ 7,500 $ 9,750 The Company had balances with VIEs as follows: Summary of Balances with Variable Interest Entities June 30, 2024 December 31, 2023 Bloom INVO, LLC Accounts receivable $ 28,500 31,500 Notes payable 489,948 482,656 Unconsolidated VIEs Accounts receivable $ 22,500 15,000

Inventory

Inventory	6 Months Ended
	Jun. 30, 2024
Inventory Disclosure [Abstract]
Inventory	Note 6 – Inventory Components of inventory are as follows: Schedule of Inventory June 30, 2024 December 31, 2023 Raw materials $ 53,480 $ 53,479 Finished goods 196,586 211,028 Total inventory $ 250,066 $ 264,507

Property and Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2024
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 7 – Property and Equipment The estimated useful lives and accumulated depreciation for equipment are as follows as of June 30, 2024, and December 31, 2023: Schedule of Estimated Useful Lives of Property and Equipment Estimated Useful Life Manufacturing equipment 6 10 Medical equipment 7 10 Office equipment 3 7 Schedule of Property and Equipment June 30, December 31, 2023 Manufacturing equipment $ 132,513 $ 132,513 Medical equipment 404,272 303,943 Office equipment 89,904 85,404 Leasehold improvements 96,817 538,151 Property, plant and equipment, gross 96,817 538,151 Less: accumulated depreciation (282,141 ) (233,593 ) Total equipment, net $ 441,365 $ 826,418 During the three months ended June 30, 2024, and 2023, the Company recorded depreciation expense of $ 25,963 19,705 During the six months ended June 30, 2024, and 2023, the Company recorded depreciation expense of $ 48,548 38,792 For the three months ended June 30, 2024, the Company recognized a gain on disposal of fixed assets of $ 50,000 For the six months ended June 30, 2024, the Company recognized a loss on disposal of fixed assets of $ 511,663

Intangible Assets & Goodwill

Intangible Assets & Goodwill	6 Months Ended
	Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets & Goodwill	Note 8 – Intangible Assets & Goodwill Components of intangible assets are as follows: Schedule of Finite-Lived Intangible Assets June 30, December 31, Tradename $ 253,000 $ 253,000 Noncompetition agreement 3,961,000 3,961,000 Goodwill 5,878,986 5,878,986 Less: accumulated amortization (529,319 ) (120,569 ) Total intangible assets $ 9,563,667 $ 9,972,417 As part of the WFI acquisition, that closed on August 10, 2023, the Company acquired a tradename valued at $ 253,000 3,961,000 5,878,986 34,000 10 15 During the three months ended June 30, 2024, and 2023, the Company recorded amortization expenses related to intangible assets of $ 204,375 0 During the six months ended June 30, 2024, and 2023, the Company recorded amortization expenses related to intangible assets of $ 408,750 0 Goodwill has an indefinite useful life and is therefore not amortized. The Company reviewed and found no indicators for impairment of the intangible assets related to the acquisition of WFI as of June 30, 2024.

Leases

Leases	6 Months Ended
	Jun. 30, 2024
Leases
Leases	Note 9 – Leases The Company has various operating lease agreements in place for its office and joint ventures. Per FASB’s ASU 2016-02, Leases Topic 842 (“ASU 2016-02”), effective January 1, 2019, the Company is required to report a right-of-use asset and corresponding liability to report the present value of the total lease payments, with appropriate interest calculation. The rate implicit in the lease was not readily determinable. Historically, the Company historically utilized the applicable federal rate as of the commencement of the lease; however, the Company has determined that utilization of the applicable federal rate was not its comparable incremental borrowing rate. The Company has since calculated the incremental borrowing rate for each lease by developing a synthetic credit rating for the Company as of the commencement date of each lease, adjusting the synthetic credit rating to reflect the collateralized nature of the incremental borrowing rate, and based on the adjusted synthetic rating and the various terms of the leases, selected the incremental borrowing rate based on the commencement date, duration of the lease, and a corresponding weight-adjusted corporate yield curve. The Company then completed a sensitivity analysis on all of its current leases and determined there was no material difference between using the applicable federal rate and the applicable incremental borrowing rate. Lease renewal options included in any lease are considered in the lease term if it is reasonably certain the Company will exercise the option to renew. The Company’s operating lease agreements do not contain any material restrictive covenants. As of June 30, 2024, the Company’s lease components included in the consolidated balance sheet were as follows: Schedule of Lease Components Lease component Balance sheet classification June 30, 2024 Assets ROU assets – operating lease Other assets $ 2,614,466 Total ROU assets $ 2,614,466 Liabilities Current operating lease liability Current liabilities $ 237,030 Long-term operating lease liability Other liabilities 2,506,543 Total lease liabilities $ 2,743,573 Future minimum lease payments as of June 30, 2024 were as follows: Schedule of Future Minimum Lease Payments 2024 235,757 2025 477,947 2026 490,122 2027 480,096 2028 and beyond 2,329,321 Total future minimum lease payments $ 4,013,243 Less: Interest (1,269,670 ) Total operating lease liabilities $ 2,743,573 For the six months ended June 30, 2024, the weighted average remaining lease term for operating leases was 102 9.0 0.2 For the six months ended June 30, 2024, the Company recognized a gain on lease termination of $ 94,551

Notes Payable

Notes Payable	6 Months Ended
	Jun. 30, 2024
Debt Disclosure [Abstract]
Notes Payable	Note 10 – Notes Payable Notes payables consisted of the following: Schedule of Notes Payable June 30, 2024 December 31, 2023 Note payable. 35% - 100 % cumulative interest. Matures on June 29, 2028 $ 1,349,757 $ 1,451,245 Note payable. 35 100 June 29, 2028 $ 1,349,757 $ 1,451,245 Related party demand notes with a 10 10 880,000 880,000 Convertible notes. 10 1.20 235,000 410,000 Convertible note. 12 1.00 275,000 - Cash advance agreement 175,332 287,604 Less debt discount and financing costs (282,101 ) (264,932 ) Total, net of discount $ 2,632,988 $ 2,763,917 Related Party Demand Notes In the fourth quarter of 2022, the Company received $ 500,000 10 10 100,000 In consideration for subscribing to the JAG Note for $ 100,000 17,500 5 10.00 In the fourth quarter of 2022, the Company received $ 200,000 100,000 60,000 15,000 25,000 100,000 75,000 25,000 These notes accrue 10 10 The financing fees for all demand notes were recorded as a debt discount and, as of June 30, 2024, the Company had fully amortized the discount. For the six months ended June 30, 2024, the Company incurred $ 40,444 January and March 2023 Convertible Notes In January and March 2023, the Company issued $ 410,000 310,000 100,000 10.00 275,000 12.00 135,000 5 19,375 20.00 The cumulative fair value of the warrants at issuance was $ 132,183 Interest on these notes accrues at a rate of ten percent ( 10 December 31, 2023 17,766 All amounts due under these notes are convertible at any time after the issuance date, in whole or in part (subject to rounding for fractional shares), at the option of the holders into the common stock at a fixed conversion price for the notes as described above. As of December 27, 2023, the Company secured written consent by the note holders of the Q1 23 Convertible Notes for the maturity date to be extended to June 30, 2024. As an incentive for the Q1 23 Convertible Note holders to approve the extension, the Company agreed to lower both the Q1 23 Convertible Notes fixed conversion price and the related warrant exercise price to $ 2.25 163,278 As of June 28, 2024, the Company secured written consent by the note holders for the Q1 23 Convertible Notes for the maturity date to be extended to December 31, 2024. As an incentive for the note holders to approve the extension, the Company agreed (a) to lower both the Q1 23 Convertible Notes fixed conversion price and the related warrant exercise price to $ 1.20 3 124,421 40,491 78,443 During the second quarter of 2024, $ 175,000 22,033 109,886 February 2023 Convertible Debentures On February 3 and February 17, 2023, the Company entered into securities purchase agreements (the “February Purchase Agreements”) with accredited investors (the “February Investors”) for the purchase of (i) convertible debentures of the Company in the aggregate original principal amount of $ 500,000 450,000 12,500 15.00 4,167 The cumulative fair value of the warrants at issuance was $ 291,207 Pursuant to the February Debentures, interest on the February Debentures accrued at a rate of eight percent ( 8 0 All amounts due under the February Debentures were convertible at any time after the issuance date, in whole or in part, at the option of the February Investors into common stock at an initial price of $ 10.40 The Company could prepay the February Debentures at any time in whole or in part by paying a sum of money equal to 105 While any portion of each February Debenture remained outstanding, if the Company received cash proceeds of more than $ 2,000,000 50 360,151 139,849 The February Warrants included anti-dilution protection whereby a subsequent offering priced below the February Warrants’ strike price then in effect would entitle the February Investors to a reduction of such strike price to the price of such subsequent offering and an increase in the February Warrant Shares determined by dividing the dollar amount for which the February Warrants are exercisable by such lower strike price. As a result of the $ 2.85 65,790 2.85 26,391 17,594 Standard Merchant Cash Advance On July 20, 2023, the Company entered into a Standard Merchant Cash Advance Agreement (the “Cash Advance Agreement”) with Cedar Advance LLC (“Cedar”) under which Cedar purchased $ 543,750 375,000 356,250 19,419.64 543,750 465,000 On August 31, 2023, the Company refinanced the Initial Advance through the purchase by Cedar of $ 746,750 515,000 134,018 390,892 643,750 674,650 16,594 0.3 9,277 64,956 The financing fees were recorded as a debt discount. For the six months ending June 30, 2024, the Company amortized $ 139,678 111,044 Revenue Loan and Security Agreement On September 29, 2023, the Company, its Chief Executive Officer, as a Key Person, and the Company’s wholly-owned subsidiaries Bio X Cell, Inc, INVO CTR, Wood Violet Fertility LLC, FLOW and Orange Blossom Fertility LLC as guarantors (the “Guarantors”), entered into a Revenue Loan and Security Agreement (the “Loan Agreement”) with Decathlon Alpha V LP (the “Lender”) under which the Lender advanced a gross amount of $ 1,500,000 35 100 The financing fees for the RSLA Loan were recorded as a debt discount. For the six months ending June 30, 2024, the Company amortized $ 1,579 12,632 108,513 Future Receipts Agreement On February 26, 2024, the Company finalized an Agreement for the Purchase and Sale of Future Receipts (the “Future Receipts Agreement”) with a buyer (the “Buyer”) under which the Buyer purchased $ 344,925 236,250 225,000 13,797 110,376 The financing fees were recorded as a debt discount. For the six months ending June 30, 2024, the Company amortized $ 89,772 30,152 FirstFire Convertible Note On April 5, 2024, the Company entered into a purchase agreement with FirstFire Global Opportunities Fund, LLC (“FirstFire”), pursuant to which FirstFire agreed to purchase, and the Company agreed to issue and sell, (i) a promissory note with an aggregate principal amount of $ 275,000 229,167 1.20 500,000 0.01 50,000 250,000 25,000 11,655 The FirstFire Note carries an interest rate of twelve percent ( 12 33,000 The financing fees for the FirstFire Note were recorded as a debt discount. For the six months ending June 30, 2024, the Company amortized $ 39,539 128,273 33,000

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2024
Related Party Transactions [Abstract]
Related Party Transactions	Note 11 – Related Party Transactions In the fourth quarter of 2022, the Company issued a series of demand promissory notes in the aggregate principal amount of $ 550,000 to a related party, JAG, a company in which the Company’s Chief Financial Officer is a beneficiary but does not have any control over its investment decisions with respect to the Company, for an aggregate purchase price of $ 500,000 . The JAG Notes accrue 10% 10% 110,000 to JAG for a purchase price of $ 100,000 . In consideration for subscribing to the JAG Note for $ 100,000 17,500 5 10.00 In the fourth quarter of 2022, the Company issued demand promissory notes in the aggregate principal amount of $ 220,000 200,000 100,000 60,000 15,000 25,000 100,000 75,000 25,000 These notes are callable with 10 days prior written notice. At maturity, the Company agreed to pay outstanding principal, a 10% financing fee, and accrued interest. For the six months ended June 30, 2024, the Company incurred $ 40,444 As of June 30, 2024, the Company owed accounts payable to related parties totaling $ 227,321 375,422

Stockholders_ Equity

Stockholders’ Equity	6 Months Ended
	Jun. 30, 2024
Equity [Abstract]
Stockholders’ Equity	Note 12 – Stockholders’ Equity Reverse Stock Split On June 28, 2023, the Company’s board of directors approved a reverse stock split of the Company’s common stock at a ratio of 1-for-20 and also approved a proportionate decrease in its authorized common stock to 6,250,000 125,000,000 the Company filed a certificate of change (with an effective date of July 28, 2023) with the Nevada Secretary of State pursuant to Nevada Revised Statutes 78.209 to effectuate a 1-for-20 reverse stock split of its outstanding common stock Increase in Authorized Common Stock On October 13, 2023, stockholders of the Company approved an increase to the number of authorized shares of the Company’s common stock from 6,250,000 50,000,000 6,250,000 50,000,000 Series A Preferred Stock On November 20, 2023, the Company filed with the Nevada Secretary of State a Certificate of Designation of Series A Convertible Preferred Stock (the “Series A Certificate of Designation”) which sets forth the rights, preferences, and privileges of the Company’s Series A Preferred Stock (the “Series A Preferred”). One million ( 1,000,000 5.00 Each share of Series A Preferred has a stated value of $ 5.00 and is convertible into shares of the Company’s common stock at a fixed conversion price equal to $ 2.20 per share, subject to adjustment. The Company may not effect the conversion of any shares of Series A Preferred if, after giving effect to the conversion or issuance, the holder, together with its affiliates, would beneficially own more than 9.99% of the Company’s outstanding common stock. Moreover, the Company may not effect the conversion of any shares of Series A Preferred if, after giving effect to the conversion or issuance, the holder, together with its affiliates, would beneficially own more than 19.99% of the Company’s outstanding common stock unless and until the Company receives the approval required by the applicable rules and regulations of The Nasdaq Stock Market LLC (or any subsequent trading market). Each share of Series A Preferred stock shall automatically convert into common stock upon the closing of a merger (the “Merger”) of INVO Merger Sub Inc., a wholly owned subsidiary of the Company (“Merger Sub”), with and into NAYA pursuant to an Agreement and Plan of Merger, as amended, by and among the Company, Merger Sub, and NAYA (the “Merger Agreement”). The holders of Series A Preferred shall be entitled to receive a pro-rata portion, on an as-if converted basis, of any dividends payable on common stock. In the event of any voluntary or involuntary liquidation, dissolution, or winding up, or sale of the Company (other than the Merger), each holder of Series A Preferred shall be entitled to receive its pro rata portion of an aggregate payment equal to (i) $ 5.00 Other than those rights provided by law, the holders of Series A Preferred shall not have any voting rights. Since the conversion of the Series A Preferred Stock is contingent on the closing of the Merger, it is not considered a mandatorily redeemable financial instrument until the closing of the Merger and therefore is not considered a liability under ASC 480. Additionally, since the Series A Preferred Stock is redeemable for the Company’s common stock upon an event within the Company’s control, it is classified as permanent equity. On December 29, 2023, the Company entered into securities purchase agreement (the “Preferred Series A SPA”) with NAYA for the purchase of 1,000,000 5.00 500,000 500,000 500,000 500,000 On January 4, 2024, the Company and NAYA closed on 100,000 500,000 Effective as of May 1, 2024, the Company entered into an Amendment (the “SPA Amendment”) to the Series A Preferred SPA. Pursuant to the SPA Amendment, the parties agreed to the following closing schedule for NAYA’s purchases of the remaining 838,800 5.00 Schedule of Closing Price for NAYA's Purchases of Remaining Shares Closing Date Shares Aggregate Purchase Price May 10, 2024 20,000 $ 100,000 May 17, 2024 30,000 $ 150,000 May 24, 2024 30,000 $ 150,000 May 31, 2024 30,000 $ 150,000 June 7, 2024 30,000 $ 150,000 June 14, 2024 30,000 $ 150,000 June 21, 2024 30,000 $ 150,000 June 28, 2024 30,000 $ 150,000 July 5, 2024 30,000 $ 150,000 On or before the closing of the Merger Agreement, to be determined in good faith by the Subscriber and the Company 598,800 $ 2,894,000 During the second quarter of 2024, the Company and NAYA closed on additional 201,280 1,006,400 Series B Preferred Stock On November 20, 2023, the Company filed with the Nevada Secretary of State a Certificate of Designation of Series B Convertible Preferred Stock (the “Series B Certificate of Designation”) which sets forth the rights, preferences, and privileges of the Company’s Series B Preferred Stock (the “Series B Preferred”). One million two hundred ( 1,200,000 5.00 Each share of Series B Preferred has a stated value of $ 5.00 5.00 19.99 Each share of Series B Preferred stock shall automatically convert into common stock upon the closing of the Merger. The holders of Series B Preferred shall be entitled to receive a pro-rata portion, on an as-if converted basis, of any dividends payable on common stock. In the event of any voluntary or involuntary liquidation, dissolution, or winding up, or sale of the Company (other than the previously announced merger with NAYA), each holder of Series B Preferred shall be entitled to receive its pro rata portion of an aggregate payment equal to (i) $ 5.00 Other than those rights provided by law, the holders of Series B Preferred shall not have any voting rights. Since the conversion of the Series B Preferred Stock is contingent on the closing of the Merger, it is not considered a mandatorily redeemable financial instrument until the closing of the Merger and therefore is not considered a liability under ASC 480. Additionally, since the Series B Preferred Stock is redeemable for the Company’s common stock upon an event within the Company’s control, it is classified as permanent equity. On November 19, 2023, the Company entered into a share exchange agreement (the “Share Exchange Agreement”) with Cytovia Therapeutics Holdings, Inc., a Delaware corporation (“Cytovia”) for Cytovia’s acquisition of 1,200,000 163,637 6.5 February 2023 Equity Purchase Agreement On February 3, 2023, the Company entered into an equity purchase agreement (the “ELOC”) and registration rights agreement (the “ELOC RRA”) with an accredited investor (the “Feb 3 Investor”) pursuant to which the Company has the right, but not the obligation, to direct the Feb 3 Investor to purchase up to $ 10.0 (i) in a minimum amount of not less than $25,000 and (ii) in a maximum amount of up to the lesser of (a) $750,000 or (b) 200% of the Company’s average daily trading value of the common stock. Also on February 3, 2023, the Company issued to the Feb 3 Investor 7,500 The obligation of the Feb 3 Investor to purchase shares of common stock pursuant to the ELOC ends on the earlier of (i) the date on which the purchases under the ELOC equal the Maximum Commitment Amount, (ii) 24 months after the date of the ELOC (February 3, 2025), (iii) written notice of termination by the Company, (iv) the date that the ELOC RRA is no longer effective after its initial effective date, or (v) the date that the Company commences a voluntary case or any person or entity commences a proceeding against the Company pursuant to or within the meaning of federal or state bankruptcy law, a custodian is appointed for the Company or for all or substantially all of its property, or the Company makes a general assignment for the benefit of its creditors (the “Commitment Period”). During the Commitment Period, and subject to the shares of common stock underlying the ELOC be registered, the price that Feb 3 Investor will pay to purchase the shares of common stock that it is obligated to purchase under the ELOC shall be 97% of the “market price,” which is defined as the lesser of (i) the lowest closing price of our common stock during the 7 trading day-period following the clearance date associated with the applicable put notice from the Company or (ii) the lowest closing bid price of the common stock on the principal trading market for the common stock (currently, the Nasdaq Capital Market) on the trading day immediately preceding a put date. To date, the Company has not been in a position to register the shares underlying the ELOC as a result of standstill agreements related to the RD Offering and the August 2023 Offering (both as defined below). March 2023 Registered Direct Offering On March 23, 2023, INVO entered into a securities purchase agreement (the “March Purchase Agreement”) with a certain institutional investor, pursuant to which the Company agreed to issue and sell to such investor (i) in a registered direct offering (the “RD Offering”), 69,000 115,000 0.20 276,000 12.60 The March Warrant (and the shares of common stock issuable upon the exercise of the March Warrant) was not registered under the Securities Act and was offered pursuant to an exemption from the registration requirements of the Securities Act provided in Section 4(a)(2) of the Securities Act and Rule 506(b) promulgated thereunder. The March Warrant is immediately exercisable upon issuance, will expire eight years from the date of issuance, and in certain circumstances may be exercised on a cashless basis. On March 27, 2023, the Company closed the RD Offering and March Warrant Placement, raising gross proceeds of approximately $ 3 3.5 383,879 August 2023 Public Offering On August 4, 2023, the Company entered into securities purchase agreements (the “Purchase Agreements”) with certain institutional and other investors, pursuant to which the Company agreed to issue and sell to such investors in a public offering (the “August 2023 Offering”), 1,580,000 2.85 2.85 1,580,000 3,160,000 The Company closed the Offering on August 8, 2023, raising gross proceeds of approximately $ 4.5 2,150,000 350,000 1,000,000 139,849 10,911 In connection with the August 2023 Offering, on August 4, 2023, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with Maxim Group LLC (the “Placement Agent”), pursuant to which (i) the Placement Agent agreed to act as placement agent on a “best efforts” basis in connection with the August 2023 Offering and (ii) the Company agreed to pay the Placement Agent an aggregate fee equal to 7.0 5 110,600 3.14 The August 2023 Offering was facilitated by the Company entering into an Amendment to Securities Purchase Agreement on July 7, 2023 (the “Armistice Amendment”) with Armistice Capital Markets Ltd. to delete Section 4.12(a) of our March 23, 2023 Securities Purchase Agreement (the “Armistice SPA”) with Armistice pursuant to which we agreed that from March 23, 2023 until 45 days after the effective date of the Resale Registration Statement (as defined below) we would not (i) issue, enter into any agreement to issue, or announce the issuance or proposed issuance of any shares of common stock or common stock equivalents or (ii) file any registration statement or any amendment or supplement thereto, other than the prospectus supplement filed in connection with that offering and the Resale Registration Statement (the “Subsequent Equity Financing Provision”). In consideration of Armistice’s agreement to enter into the Armistice Amendment and delete the Subsequent Equity Financing Provision from the Armistice SPA, we agreed to pay Armistice a fee a $ 1,000,000 2.85 Triton Purchase Agreement On March 27, 2024, the Company entered into a purchase agreement (the “Triton Purchase Agreement”) with Triton Funds LP (“Triton”), pursuant to which the Company agreed to sell, and Triton agreed to purchase, upon the Company’s request in one or more transactions, up to 1,000,000 0.0001 850,000 0.85 The Triton Purchase Agreement expires upon the earlier of the sale of all 1,000,000 shares of the Company’s common stock or December 31, 2024. Among other limitations, unless otherwise agreed upon by Triton, each individual sale of shares of common stock will be limited to no more than the number of shares of common stock that would result in the direct or indirect beneficial ownership by Triton of more than 9.99% of the then-outstanding shares of common stock. In addition, the total cumulative number of shares of common stock that may be issued to Triton under the Triton Purchase Agreement may not exceed the requirements of Nasdaq Listing Rule 5635(d), except that such limitation will not apply if the Company obtains stockholder approval of the shares of common stock to be issued under the Triton Purchase Agreement, if necessary, in accordance with the requirements of Nasdaq Listing Rule 5635(d). The Triton Purchase Agreement provides that the Company will file a prospectus supplement (the “Prospectus Supplement”) to its Registration Statement on Form S-3, which was declared effective on April 16, 2021 (File No. 333-255096) (the “Base Registration Statement”), covering the offering and sale of the shares of common stock to Triton pursuant to the Triton Purchase Agreement. Triton’s obligation to purchase shares of common stock under the Triton Purchase Agreement is conditioned upon, among other things, the filing of the Prospectus Supplement and the Base Registration Statement remaining effective. The Triton Purchase Agreement contains customary representations, warranties, and covenants by each of the Company and Triton. Actual sales of shares of common stock to Triton will depend on a variety of factors to be determined by the Company from time to time, including, among others, market conditions, the trading price of the common stock, and determinations by the Company as to the appropriate sources of funding for the Company and its operations. Triton has no right to require any sales of shares of common stock by the Company but is obligated to make purchases of shares of common stock from the Company from time to time, pursuant to directions from the Company, in accordance with the Triton Purchase Agreement. During the term of the Triton Purchase Agreement, Triton has covenanted not to cause or engage in any short selling of shares of common stock. On March 27, 2024, the Company delivered a purchase notice for 260,000 260,000 185,000 75,000 10,131 On April 16, 2024, the Company delivered a purchase notice for 185,000 155,000 Six Months Ended June 30, 2024 During the six months of 2024, the Company issued 194,655 202,448 On January 31, 2024, the Company issued 100,000 500,000 61,200 306,000 140,080 700,404 In April 2024, the Company issued 260,000 165,131 In April 2024, the Company issued 807,000 971,012 In April 2024, the Company issued 109,886 197,033

Equity-Based Compensation

Equity-Based Compensation	6 Months Ended
	Jun. 30, 2024
Equity [Abstract]
Equity-Based Compensation	Note 13 – Equity-Based Compensation Equity Incentive Plans In October 2019, the Company adopted its 2019 Incentive Plan (the “2019 Plan”). Under the 2019 Plan, the Company’s board of directors is authorized to grant stock options to purchase common stock, restricted stock units, and restricted shares of common stock to its employees, directors, and consultants. The 2019 Plan initially provided for the issuance of 25,000 A provision in the 2019 Plan provides for an automatic annual increase equal to 6% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year. 149,551 311,049 Options granted under the 2019 Plan generally have a life of 3 10 140,336 The following table sets forth the activity of the options to purchase common stock under the 2019 Plan. Schedule of Stock Options Activity Number of Shares Weighted Average Exercise Price Aggregate Intrinsic Value Outstanding as of December 31, 2023 106,753 $ 41.90 $ - Granted - - - Exercised - - - Canceled (8,761 ) 31.58 - Balance as of June 30, 2024 97,992 $ 35.20 $ - Exercisable as of June 30, 2024 88,218 $ 51.67 $ - The fair value of each option granted is estimated as of the grant date using the Black-Scholes option pricing model with the following assumptions: Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions Six months ended June 30, 2024 2023 Risk-free interest rate range - % 3.6 3.69 % Expected life of option-years - 5 5.63 Expected stock price volatility - % 106.6 114.9 % Expected dividend yield - % - % The risk-free interest rate is based on U.S. Treasury interest rates, the terms of which are consistent with the expected life of the stock options. Expected volatility is based upon the average historical volatility of the common stock over the period commensurate with the expected term of the related instrument. The expected life and estimated post-employment termination behavior is based upon historical experience of homogeneous groups, executives and non-executives, within the Company. The Company does not currently pay dividends on its common stock, nor does it expect to do so in the foreseeable future. Schedule of Share Based Payments Arrangements Options Exercised and Options Vested Total Intrinsic Value of Options Exercised Total Fair Value of Vested Year ended December 31, 2023 $ - $ 1,049,109 Six months ended June 30, 2024 $ - $ 140,336 For the six months ended June 30, 2024, there were no options granted. The Company estimates the fair value of options at the grant date using the Black-Scholes model. For all stock options granted through June 30, 2024, the weighted average remaining service period is 1 Restricted Stock and Restricted Stock Units In the six months ended June 30, 2024, the Company did no one year The following table summarizes the Company’s restricted stock awards activity under the 2019 Plan during the six months ended June 30, 2024: Schedule of Aggregate Restricted Stock Awards and Restricted Stock Unit Activity Number of Unvested Shares Weighted Average Grant Date Fair Value Aggregate Value of Shares Balance as of December 31, 2023 25 $ 18.42 $ 5,525 Granted - - - Vested - - - Forfeitures - - - Balance as of June 30, 2024 25 $ 18.42 $ 5,525

Unit Purchase Options and Warra

Unit Purchase Options and Warrants	6 Months Ended
	Jun. 30, 2024
Unit Purchase Options And Warrants
Unit Purchase Options and Warrants	Note 14 – Unit Purchase Options and Warrants The following table sets forth the activity of unit purchase options: Schedule of Unit Purchase Option Activity Number of Unit Purchase Options Weighted Average Exercise Price Aggregate Intrinsic Value Outstanding as of December 31, 2023 $ 4,649 $ 64.00 $ - Granted - - - Exercised - - - Canceled - - - Balance as of June 30, 2024 $ 4,649 $ 64.00 $ - The following table sets forth the activity of warrants: Schedule of Warrants Activity Number of Warrants Weighted Average Exercise Price Aggregate Intrinsic Value Outstanding as of December 31, 2023 3,488,620 $ 3.95 $ - Granted 1,444,812 1.80 - Exercised (807,000 ) 1.20 - Canceled - - - Balance as of June 30, 2024 4,126,432 $ 1.79 $ - Warrants related to January and March 2023 Convertible Notes In January and March 2023, the Company issued 5 19,375 20.00 2.25 163,278 Warrants related to February 2023 Convertible Debentures On February 3 and February 17, 2023, the Company issued warrants (the “February Warrants”) to purchase 12,500 15.00 The February Warrants included anti-dilution protection whereby a subsequent offering priced below the February Warrants’ strike price then in effect would entitle the February Investors to a reduction of such strike price to the price of such subsequent offering and an increase in the February Warrant Shares determined by dividing the dollar amount for which the February Warrants are exercisable by such lower strike price. As a result of the $ 2.85 65,790 2.85 26,391 17,594 Warrants related to March 2023 Registered Direct Offering On March 23, 2023, INVO entered into a securities purchase agreement (the “March Purchase Agreement”) with a certain institutional investor, pursuant to which the Company agreed to issue and sell to such investor (i) in a registered direct offering (the “RD Offering”), 69,000 115,000 0.20 276,000 12.60 The March Warrant (and the shares of common stock issuable upon the exercise of the March Warrant) was not registered under the Securities Act and was offered pursuant to an exemption from the registration requirements of the Securities Act provided in Section 4(a)(2) of the Securities Act and Rule 506(b) promulgated thereunder. The March Warrant is immediately exercisable upon issuance, will expire eight years from the date of issuance, and in certain circumstances may be exercised on a cashless basis. On July 7, 2023, the Company entered into an Amendment to Securities Purchase Agreement (the “Armistice Amendment”) with Armistice Capital Markets Ltd. to delete Section 4.12(a) of our March 23, 2023 Securities Purchase Agreement (the “Armistice SPA”) with Armistice pursuant to which the Company agreed that from March 23, 2023 until 45 days after the effective date of the Resale Registration Statement (as defined below) the Company would not (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of common stock or common stock equivalents or (ii) file any registration statement or any amendment or supplement thereto, other than the prospectus supplement filed in connection with that offering and the Resale Registration Statement (the “Subsequent Equity Financing Provision”). In consideration of Armistice’s agreement to enter into the Armistice Amendment and delete the Subsequent Equity Financing Provision from the Armistice SPA, the Company agreed to pay Armistice a fee a $ 1,000,000 2.85 Warrants related to August 2023 Public Offering In the August 2023 Offering, the Company issued and sold 1,580,000 2.85 2.85 1,580,000 3,160,000 In connection with the August 2023 Offering, on August 4, 2023, the Company issued to the Placement Agent Placement Agent Warrants to purchase 110,600 3.14 On April 17, 2024, the Company reduced the exercise price of the August 2023 Warrants from $ 2.85 1.20 250,635 In April 2024, the Company issued 807,000 968,400 Triton Private Placement Warrants On March 27, 2024, the Company issued to Triton private placement warrants (the “Triton Warrants”) to purchase up to 1,000,000 2.00 971,012 FirstFire Warrants On April 5, 2024, the Company entered into a purchase agreement with FirstFire pursuant to which FirstFire agreed to purchase, and the Company agreed to issue and sell, (i) the FirstFire Note, (ii) a warrant (the “First Warrant”) to purchase 229,167 shares of the Company’s common stock at an exercise price of $ 1.20 per share, (iii) a warrant (the “Second Warrant”) to purchase 500,000 shares of common stock at an exercise price of $ 0.01 issued to FirstFire, and (iv) 50,000 shares of common stock, for a purchase price of $ 250,000 . Carter, Terry, & Company, Inc. acted as placement agent for the transaction, for which it received a cash fee of $ 25,000 and 11,655 restricted shares of the Company’s common stock. The First Warrant is to be immediately exercisable and will expire five years from the issuance date. The Second Warrant will only become exercisable if an event of default occurs under the FirstFire Note and will expire five years from the date on which such an event of default occurs (a “Triggering Event Date”). The Second Warrant includes a ‘Returnable Warrant’ clause, providing that the Second Warrant shall be cancelled and returned to the Company if the Note is fully extinguished before any Triggering Event Date.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Note 15 – Income Taxes The Company uses the asset and liability method to account for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. If a carryforward exists, the Company decides as to whether the carryforward will be utilized in the future. Currently, a valuation allowance is established for all deferred tax assets and carryforwards as their recoverability is deemed to be uncertain. If the Company’s expectations for future operating results at the federal or at the state jurisdiction level vary from actual results due to changes in healthcare regulations, general economic conditions, or other factors, it may need to adjust the valuation allowance, for all or a portion of the Company’s deferred tax assets. The Company’s income tax expense in future periods will be reduced or increased to the extent of offsetting decreases or increases, respectively, in the Company’s valuation allowance in the period when the change in circumstances occurs. These changes could have a significant impact on the Company’s future earnings. Income tax expense was $ 0 1,836 2,865 0 0

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 16 – Commitments and Contingencies Insurance The Company’s insurance coverage is carried with third-party insurers and includes (i) general liability insurance covering third-party exposures, (ii) statutory workers’ compensation insurance, (iii) excess liability insurance above the established primary limits for general liability and automobile liability insurance, (iv) property insurance, which covers the replacement value of real and personal property and includes business interruption, and (v) insurance covering our directors and officers for acts related to our business activities. All coverage is subject to certain limits and deductibles, the terms and conditions of which are common for companies with similar types of operations. Legal Matters The Company is not currently subject to any material legal proceedings; however, it could be subject to legal proceedings and claims from time to time in the ordinary course of its business, or legal proceedings it considered immaterial may in the future become material. Regardless of the outcome, litigation can, among other things, be time consuming and expensive to resolve, and can divert management resources. NAYA Merger Agreement On October 22, 2023, the Company, Merger Sub, and NAYA entered into the Merger Agreement. Unless the Merger Agreement is terminated before the consummation of the Merger, at the effective time and as a result of the Merger, each share of Class A common stock, par value $ 0.000001 7.33333 0.0001 18,150,000 Unless the Merger Agreement is terminated before the consummation of the Merger, immediately following the effective time of the Merger NAYA’s current chairman and chief executive officer will be named chairman and chief executive officer of the Company, and the board of directors will be comprised of at least seven (7) directors, of which (i) one will be the Company’s Chief Executive Officer, and (ii) six (6) shall be identified by NAYA, of which five (5) shall be independent directors. Pursuant to the original Merger Agreement, the completion of the Merger is subject to satisfaction or waiver of certain customary mutual closing conditions, including (1) the adoption of the Merger Agreement by the stockholders of the Company and NAYA, (2) the absence of any injunction or other order issued by a court of competent jurisdiction or applicable law or legal prohibition prohibiting or making illegal the consummation of the Merger, (3) the completion of due diligence, (4) the completion of an interim private offering of shares of Company common stock at a price that is a premium to the market price of the Company common stock in an estimated amount of $ 5,000,000 5.00 5,000,000 5.00 The original Merger Agreement contains termination rights for each of the Company and NAYA, including, among others: (1) if the consummation of the Merger does not occur on or before December 31, 2023 (the “End Date”) (which has since been extended to June 30, 2024), except that any party whose material breach of the Merger Agreement caused or was the primary contributing factor that resulted in the failure of the Merger to be consummated on or before the End Date, (2) if any governmental authority has enacted any law or order making illegal, permanently enjoining, or otherwise permanently prohibiting the consummation of the Merger, and (3) if the required vote of the stockholders of either the Company or NAYA has not been obtained. The Merger Agreement contains additional termination rights for NAYA, including, among others: (1) if the Company materially breaches its non-solicitation obligations or fails to take all action necessary to hold a stockholder meeting to approve the transactions contemplated by the Merger Agreement, (2) if the aggregate of the liabilities of the Company, excluding certain specified liabilities, exceeds $ 5,000,000 If all of NAYA’s conditions to closing are satisfied or waived and NAYA fails to consummate the Merger, NAYA would be required to pay the Company a termination fee of $ 1,000,000 1,000,000 On December 27, 2023, the Company entered into a second amendment (“Second Amendment”) to the Merger Agreement. Pursuant to the Second Amendment, the parties agreed to extend the End Date to April 30, 2024. The parties further agreed to modify the closing condition for the Interim PIPE from a private offering of shares of Company common stock at a price that is a premium to the market price of the Company common stock in an estimated amount of $ 5,000,000 5.00 The parties further agreed to the following schedule (the “Minimum Interim PIPE Schedule”) for the initial $2,000,000: (1) $500,000 no later than December 29, 2023, (2) $500,000 no later than January 19, 2024, (3) $500,000 no later than February 2, 2024, and (4) $500,000 no later than February 16, 2024. Effective as of May 1, 2024, the Company entered into third amendment (“Third Amendment”) to the Merger Agreement. Pursuant to the Third Amendment, the parties agreed to extend the End Date to June 30, 2024. The parties further agreed to modify the definition of an “Interim PIPE” to mean (a) a sale of shares of the Company’s Series A Preferred Stock pursuant to the Series A Preferred SPA, as amended (“Phase 1”), plus (b) a sale of shares of the Company’s preferred stock at a price per share of $ 5.00 As of the date of this filing, NAYA has purchased $ 1,506,404 As of the date of this filing, the End Date of the Merger Agreement has not been extended. Although the funding levels under the Series A Preferred SPA, as amended, were not fully met, the Company is in negotiations with NAYA to further amend the Merger Agreement and the Series A Preferred SPA; however, there can be no assurance that the parties will amend either or both agreements.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2024
Subsequent Events [Abstract]
Subsequent Events	Note 17 – Subsequent Events In August 2024, the Company issued 42,000

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Description of Business	Description of Business INVO Bioscience, Inc. (“INVO” or the “Company”) is a healthcare services company dedicated to expanding access to fertility care around the world. The Company’s commercial strategy is primarily focused on operating fertility-focused clinics, which include the opening of “INVO Centers” dedicated primarily to offering the intravaginal culture (“IVC”) procedure enabled by its INVOcell® medical device (“INVOcell”) and the acquisition of US-based, profitable in vitro fertilization (“IVF”) clinics. The Company has two operational INVO Centers in the United States and completed its first IVF clinic acquisition in August 2023. The Company also continues to engage in the sale and distribution of its INVOcell technology solution into existing independently owned and operated fertility clinics.
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements present on a consolidated basis the accounts of the Company and its wholly owned subsidiaries and controlled affiliates. The Company presents noncontrolling interest within the equity section of its consolidated balance sheets and the amount of consolidated net income (loss) that is attributable to the Company and to the noncontrolling interest in its consolidated statement of operations. All significant intercompany accounts and transactions have been eliminated in consolidation. The Company uses the equity method of accounting when it owns an interest in an entity whereby it can exert significant influence over but cannot control the entity’s operations. The preparation of the Company’s consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. The Company considers events or transactions that have occurred after the consolidated balance sheet date of June 30, 2024, but prior to the filing of the consolidated financial statements with the SEC in this Quarterly Report on Form 10-Q, to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure, as applicable. Subsequent events have been evaluated through the date of the filing of this Quarterly Report on Form 10-Q.
Reclassifications	Reclassifications Certain amounts in the consolidated financial statements for the prior year have been reclassified to conform to the current year presentation. These reclassifications had no impact on net earnings, financial position, or cash flows.
Business Segments	Business Segments The Company operates in one
Business Acquisitions	Business Acquisitions The Company accounts for all business acquisitions at fair value and expenses acquisition costs as they are incurred. Any identifiable assets acquired and liabilities assumed are recognized and measured at their respective fair values on the acquisition date. If information about facts and circumstances existing as of the acquisition date is incomplete at the end of the reporting period in which a business acquisition occurs, the Company will report provisional amounts for the items for which the accounting is incomplete. The measurement period ends once the Company receives sufficient information to finalize the fair values; however, the period will not exceed one year from the acquisition date. Any adjustments to provisional amounts that are identified during the measurement period are recognized in the reporting period in which the adjustment amounts are determined.
Variable Interest Entities	Variable Interest Entities The Company’s consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries, and variable interest entities (“VIE”), where the Company is the primary beneficiary under the provisions of ASC 810, Consolidation (“ASC 810”). A VIE must be consolidated by its primary beneficiary when, along with its affiliates and agents, the primary beneficiary has both (i) the power to direct the activities that most significantly impact the VIE’s economic performance, and (ii) the obligation to absorb losses or the right to receive the benefits of the VIE that could potentially be significant to the VIE. The Company reconsiders whether an entity is still a VIE only upon certain triggering events and continually assesses its consolidated VIEs to determine if it continues to be the primary beneficiary. See “Note 3 – Variable Interest Entities” for additional information on the Company’s VIEs.
Equity Method Investments	Equity Method Investments Investments in unconsolidated affiliates, over which the Company exerts significant influence but does not control or otherwise consolidate, are accounted for using the equity method. Equity method investments are initially recorded at cost. These investments are included in investment in joint ventures in the accompanying consolidated balance sheets. The Company’s share of the profits and losses from these investments is reported in loss from equity method joint venture in the accompanying consolidated statements of operations. The Company monitors its investments for other-than-temporary impairment by considering factors such as current economic and market conditions and the operating performance of the investees and records reductions in carrying values when necessary.
Use of Estimates	Use of Estimates In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents For financial statement presentation purposes, the Company considers time deposits, certificates of deposit, and all highly liquid investments with original maturities of three months or less to be cash and cash equivalents. At times, cash and cash equivalents balances exceed amounts insured by the Federal Deposit Insurance Corporation.
Inventory	Inventory Inventories consist of raw materials, work in process and finished goods and are stated at the lower of cost or net realizable value, using the first-in, first-out method as a cost flow method.
Property and Equipment	Property and Equipment The Company records property and equipment at cost. Property and equipment are depreciated using the straight-line method over the estimated economic lives of the assets, which are from 3 10
Long- Lived Assets	Long- Lived Assets Long-lived assets and certain identifiable assets related to those assets are periodically reviewed for impairment whenever circumstances and situations change such that there is an indication that the carrying amounts may not be recoverable. If the non-discounted future cash flows of the asset are less than their carrying amount, their carrying amounts are reduced to fair value and an impairment loss recognized. There was no
Fair Value of Financial Instruments	Fair Value of Financial Instruments ASC 825-10-50, “Disclosures about Fair Value of Financial Instruments,” requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. Effective January 1, 2008, the Company adopted ASC 820-10, “Fair Value Measurements”, which provides a framework for measuring fair value under GAAP. ASC 820-10 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 requires that valuation techniques maximize the use of observable inputs and minimize the use of unobservable inputs.
Income Taxes	Income Taxes The Company is subject to income taxes in the United States and its domestic tax liabilities are subject to the allocation of expenses in multiple state jurisdictions. The Company uses the asset and liability method to account for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The recoverability of deferred tax assets is evaluated by assessing the adequacy of future expected taxable income from all sources, including taxable income in prior carryback years, reversal of taxable temporary differences, forecasted operating earnings, and available tax planning strategies. To the extent the Company does not consider it more-likely-than-not that a deferred tax asset will be recovered, a valuation allowance is established.
Concentration of Credit Risk	Concentration of Credit Risk Cash includes amounts deposited in financial institutions in excess of insurable Federal Deposit Insurance Corporation (“FDIC”) limits. As of June 30, 2024, the Company had cash balances in excess of FDIC limits.
Revenue Recognition	Revenue Recognition The Company recognizes revenue on arrangements in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”). The core principle of ASC 606 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services ASC 606 requires companies to assess their contracts to determine the timing and amount of revenue to recognize under the new revenue standard. The model has a five-step approach: 1. Identify the contract with the customer. 2. Identify the performance obligations in the contract. 3. Determine the total transaction price. 4. Allocate the total transaction price to each performance obligation in the contract. 5. Recognize as revenue when (or as) each performance obligation is satisfied. Revenue generated from the sale of INVOcell is typically recognized at the time the product is shipped, at which time the title passes to the customer, and there are no further performance obligations. Revenue generated from clinical and lab services related at the Company’s affiliated INVO Centers is typically recognized at the time the service is performed.
Stock Based Compensation	Stock Based Compensation The Company accounts for stock-based compensation under the provisions of Accounting Standards Codification (“ASC”) subtopic 718-10, Compensation (“ASC 718-10”). This statement requires the Company to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized over the period in which the employee is required to provide service or based on performance goals in exchange for the award, which is usually the vesting period.
Loss Per Share	Loss Per Share Basic loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding. Diluted earnings per share are computed similarly to basic earnings per share except that the denominator is increased to include potentially dilutive securities. The Company’s diluted loss per share is the same as the basic loss per share for the three months ended June 30, 2024, and 2023, as the inclusion of any potential shares would have had an anti-dilutive effect due to the Company generating a loss. Schedule of Earnings Per Share Basic and Diluted 2024 2023 2024 2023 Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Net loss (numerator) $ (2,245,170 ) (2,240,511 ) (3,841,683 ) (4,791,390 ) Basic and diluted weighted-average number of common shares outstanding (denominator) 3,609,812 732,255 3,072,877 677,684 Basic and diluted net loss per common share (0.62 ) (3.06 ) (1.25 ) (7.07 ) The Company has excluded the following dilutive securities from the calculation of fully diluted shares outstanding because the result would have been anti-dilutive: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share 2024 2023 As of June 30, 2024 2023 Options 97,992 121,255 Convertible notes and interest 532,289 55,120 Preferred stock 1,884,727 - Warrants and unit purchase options 4,131,081 348,151 Total 6,646,089 524,526
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements The Company has reviewed all recently issued, but not yet effective, accounting pronouncements, and does not believe the future adoption of any such pronouncements will have a material impact on its financial condition or the results of its operations.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Schedule of Earnings Per Share Basic and Diluted	Schedule of Earnings Per Share Basic and Diluted 2024 2023 2024 2023 Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Net loss (numerator) $ (2,245,170 ) (2,240,511 ) (3,841,683 ) (4,791,390 ) Basic and diluted weighted-average number of common shares outstanding (denominator) 3,609,812 732,255 3,072,877 677,684 Basic and diluted net loss per common share (0.62 ) (3.06 ) (1.25 ) (7.07 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The Company has excluded the following dilutive securities from the calculation of fully diluted shares outstanding because the result would have been anti-dilutive: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share 2024 2023 As of June 30, 2024 2023 Options 97,992 121,255 Convertible notes and interest 532,289 55,120 Preferred stock 1,884,727 - Warrants and unit purchase options 4,131,081 348,151 Total 6,646,089 524,526

Business Combinations (Tables)

Business Combinations (Tables)	6 Months Ended
	Jun. 30, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]
Schedule of Allocation of Purchase Price	The following allocation of the purchase price is as follows: Schedule of Allocation of Purchase Price Consideration given: Cash 2,150,000 Holdback 350,000 Additional payments 7,500,000 Business acquisition cost 10,000,000 Assets and liabilities acquired: FLOW intercompany receivable 528,756 Accounts receivable 214,972 Property and equipment, net 25,292 Other current assets 56,274 Tradename 253,000 Noncompetition agreement 3,961,000 Goodwill 5,878,986 Deferred revenue (389,524 ) WFRSA intercompany note (528,756 ) Total assets and liabilities acquired 10,000,000

Variable Interest Entities (Tab

Variable Interest Entities (Tables)	6 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Investments in Unconsolidated Variable Interest Entities	The following table summarizes our investments in unconsolidated VIEs: Schedule of Investments in Unconsolidated Variable Interest Entities Carrying Value as of Location Percentage June 30, December 31, 2023 HRCFG INVO, LLC Alabama, United States 50 % $ 844,198 916,248 Positib Fertility, S.A. de C.V. Mexico 33 % - - Total investment in unconsolidated VIEs $ 844,198 916,248
Schedule of Earnings from Investments in Unconsolidated Variable Interest Entities	Earnings from investments in unconsolidated VIEs were as follows: Schedule of Earnings from Investments in Unconsolidated Variable Interest Entities 2024 2023 2024 2023 Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 HRCFG INVO, LLC $ 17,846 $ 19,474 $ 17,950 $ 805 Positib Fertility, S.A. de C.V. - (15,686 ) - (24,752 ) Total earnings (loss) from unconsolidated VIEs 17,846 3,788 17,950 (23,947 )
Schedule of Financial Information of Investments in Unconsolidated Variable Interest Entities	The following tables summarize the combined unaudited financial information of our unconsolidated VIEs: Schedule of Financial Information of Investments in Unconsolidated Variable Interest Entities 2024 2023 2024 2023 Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Statements of operations: Operating revenue $ 333,308 $ 458,069 $ 665,622 $ 807,396 Operating expenses (297,616 ) (466,184 ) (629,722 ) (880,050 ) Net profit (loss) 35,692 (8,115 ) 35,900 (72,654 ) June 30, 2024 December 31, 2023 Balance sheets: Current assets $ 286,582 288,369 Long-term assets 991,387 1,026,873 Current liabilities (517,415 ) (510,091 ) Long-term liabilities (123,060 ) (123,060 ) Net assets $ 637,494 682,091

Agreements and Transactions w_2

Agreements and Transactions with VIE’s (Tables)	6 Months Ended
	Jun. 30, 2024
Agreements And Transactions With Vies
Summary of Transaction with Variable Interest Entities	The following table summarizes the Company’s transactions with VIEs: Summary of Transaction with Variable Interest Entities 2024 2023 2024 2023 Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Bloom INVO, LLC INVOcell revenue $ 15,000 $ 6,000 $ 25,500 $ 10,500 Unconsolidated VIEs INVOcell revenue $ - $ 6,750 $ 7,500 $ 9,750
Summary of Balances with Variable Interest Entities	The Company had balances with VIEs as follows: Summary of Balances with Variable Interest Entities June 30, 2024 December 31, 2023 Bloom INVO, LLC Accounts receivable $ 28,500 31,500 Notes payable 489,948 482,656 Unconsolidated VIEs Accounts receivable $ 22,500 15,000

Inventory (Tables)

Inventory (Tables)	6 Months Ended
	Jun. 30, 2024
Inventory Disclosure [Abstract]
Schedule of Inventory	Components of inventory are as follows: Schedule of Inventory June 30, 2024 December 31, 2023 Raw materials $ 53,480 $ 53,479 Finished goods 196,586 211,028 Total inventory $ 250,066 $ 264,507

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2024
Property, Plant and Equipment [Abstract]
Schedule of Estimated Useful Lives of Property and Equipment	The estimated useful lives and accumulated depreciation for equipment are as follows as of June 30, 2024, and December 31, 2023: Schedule of Estimated Useful Lives of Property and Equipment Estimated Useful Life Manufacturing equipment 6 10 Medical equipment 7 10 Office equipment 3 7
Schedule of Property and Equipment	Schedule of Property and Equipment June 30, December 31, 2023 Manufacturing equipment $ 132,513 $ 132,513 Medical equipment 404,272 303,943 Office equipment 89,904 85,404 Leasehold improvements 96,817 538,151 Property, plant and equipment, gross 96,817 538,151 Less: accumulated depreciation (282,141 ) (233,593 ) Total equipment, net $ 441,365 $ 826,418

Intangible Assets & Goodwill (T

Intangible Assets & Goodwill (Tables)	6 Months Ended
	Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets	Components of intangible assets are as follows: Schedule of Finite-Lived Intangible Assets June 30, December 31, Tradename $ 253,000 $ 253,000 Noncompetition agreement 3,961,000 3,961,000 Goodwill 5,878,986 5,878,986 Less: accumulated amortization (529,319 ) (120,569 ) Total intangible assets $ 9,563,667 $ 9,972,417

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2024
Leases
Schedule of Lease Components	As of June 30, 2024, the Company’s lease components included in the consolidated balance sheet were as follows: Schedule of Lease Components Lease component Balance sheet classification June 30, 2024 Assets ROU assets – operating lease Other assets $ 2,614,466 Total ROU assets $ 2,614,466 Liabilities Current operating lease liability Current liabilities $ 237,030 Long-term operating lease liability Other liabilities 2,506,543 Total lease liabilities $ 2,743,573
Schedule of Future Minimum Lease Payments	Future minimum lease payments as of June 30, 2024 were as follows: Schedule of Future Minimum Lease Payments 2024 235,757 2025 477,947 2026 490,122 2027 480,096 2028 and beyond 2,329,321 Total future minimum lease payments $ 4,013,243 Less: Interest (1,269,670 ) Total operating lease liabilities $ 2,743,573

Notes Payable (Tables)

Notes Payable (Tables)	6 Months Ended
	Jun. 30, 2024
Debt Disclosure [Abstract]
Schedule of Notes Payable	Notes payables consisted of the following: Schedule of Notes Payable June 30, 2024 December 31, 2023 Note payable. 35% - 100 % cumulative interest. Matures on June 29, 2028 $ 1,349,757 $ 1,451,245 Note payable. 35 100 June 29, 2028 $ 1,349,757 $ 1,451,245 Related party demand notes with a 10 10 880,000 880,000 Convertible notes. 10 1.20 235,000 410,000 Convertible note. 12 1.00 275,000 - Cash advance agreement 175,332 287,604 Less debt discount and financing costs (282,101 ) (264,932 ) Total, net of discount $ 2,632,988 $ 2,763,917

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	6 Months Ended
	Jun. 30, 2024
Equity [Abstract]
Schedule of Closing Price for NAYA's Purchases of Remaining Shares	Schedule of Closing Price for NAYA's Purchases of Remaining Shares Closing Date Shares Aggregate Purchase Price May 10, 2024 20,000 $ 100,000 May 17, 2024 30,000 $ 150,000 May 24, 2024 30,000 $ 150,000 May 31, 2024 30,000 $ 150,000 June 7, 2024 30,000 $ 150,000 June 14, 2024 30,000 $ 150,000 June 21, 2024 30,000 $ 150,000 June 28, 2024 30,000 $ 150,000 July 5, 2024 30,000 $ 150,000 On or before the closing of the Merger Agreement, to be determined in good faith by the Subscriber and the Company 598,800 $ 2,894,000

Equity-Based Compensation (Tabl

Equity-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2024
Equity [Abstract]
Schedule of Stock Options Activity	The following table sets forth the activity of the options to purchase common stock under the 2019 Plan. Schedule of Stock Options Activity Number of Shares Weighted Average Exercise Price Aggregate Intrinsic Value Outstanding as of December 31, 2023 106,753 $ 41.90 $ - Granted - - - Exercised - - - Canceled (8,761 ) 31.58 - Balance as of June 30, 2024 97,992 $ 35.20 $ - Exercisable as of June 30, 2024 88,218 $ 51.67 $ -
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions	The fair value of each option granted is estimated as of the grant date using the Black-Scholes option pricing model with the following assumptions: Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions Six months ended June 30, 2024 2023 Risk-free interest rate range - % 3.6 3.69 % Expected life of option-years - 5 5.63 Expected stock price volatility - % 106.6 114.9 % Expected dividend yield - % - %
Schedule of Share Based Payments Arrangements Options Exercised and Options Vested	Schedule of Share Based Payments Arrangements Options Exercised and Options Vested Total Intrinsic Value of Options Exercised Total Fair Value of Vested Year ended December 31, 2023 $ - $ 1,049,109 Six months ended June 30, 2024 $ - $ 140,336
Schedule of Aggregate Restricted Stock Awards and Restricted Stock Unit Activity	The following table summarizes the Company’s restricted stock awards activity under the 2019 Plan during the six months ended June 30, 2024: Schedule of Aggregate Restricted Stock Awards and Restricted Stock Unit Activity Number of Unvested Shares Weighted Average Grant Date Fair Value Aggregate Value of Shares Balance as of December 31, 2023 25 $ 18.42 $ 5,525 Granted - - - Vested - - - Forfeitures - - - Balance as of June 30, 2024 25 $ 18.42 $ 5,525

Unit Purchase Options and War_2

Unit Purchase Options and Warrants (Tables)	6 Months Ended
	Jun. 30, 2024
Unit Purchase Options And Warrants
Schedule of Unit Purchase Option Activity	The following table sets forth the activity of unit purchase options: Schedule of Unit Purchase Option Activity Number of Unit Purchase Options Weighted Average Exercise Price Aggregate Intrinsic Value Outstanding as of December 31, 2023 $ 4,649 $ 64.00 $ - Granted - - - Exercised - - - Canceled - - - Balance as of June 30, 2024 $ 4,649 $ 64.00 $ -
Schedule of Warrants Activity	The following table sets forth the activity of warrants: Schedule of Warrants Activity Number of Warrants Weighted Average Exercise Price Aggregate Intrinsic Value Outstanding as of December 31, 2023 3,488,620 $ 3.95 $ - Granted 1,444,812 1.80 - Exercised (807,000 ) 1.20 - Canceled - - - Balance as of June 30, 2024 4,126,432 $ 1.79 $ -

Schedule of Earnings Per Share

Schedule of Earnings Per Share Basic and Diluted (Details) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023
Accounting Policies [Abstract]
Net loss (numerator)	$ (2,245,170)	$ (1,596,513)	$ (2,240,511)	$ (2,550,879)	$ (3,841,683)	$ (4,791,390)
Basic weighted-average number of common shares outstanding (denominator)	3,609,812		732,255		3,072,877	677,684
Diluted weighted-average number of common shares outstanding (denominator)	3,609,812		732,255		3,072,877	677,684
Basic net loss per common share	$ (0.62)		$ (3.06)		$ (1.25)	$ (7.07)
Diluted net loss per common share	$ (0.62)		$ (3.06)		$ (1.25)	$ (7.07)

Schedule of Antidilutive Securi

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	6,646,089	524,526
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	97,992	121,255
Convertible Notes and Interest [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	532,289	55,120
Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	1,884,727
Warrants And Unit Purchase Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	4,131,081	348,151

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative)	6 Months Ended
	Jun. 30, 2024 USD ($) Segment	Jun. 30, 2023 USD ($)
Property, Plant and Equipment [Line Items]
Number of operating segment | Segment	1
Impairment of intangible assets | $	$ 0	$ 0
Minimum [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment estimated useful life	3 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment estimated useful life	10 years

Liquidity (Details Narrative)

Liquidity (Details Narrative) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Net income loss	$ 2,245,170	$ 1,596,513	$ 2,240,511	$ 2,550,879	$ 3,841,683	$ 4,791,390
Accumulated deficit	61,910,463				61,910,463		$ 57,818,145
Net income loss related to non cash expenses					2,600,000	$ 1,400,000
Preferred Stock [Member]
Net proceeds					1,500,000
Warrant [Member]
Net proceeds					900,000
Proceeds from sale of notes					400,000
Common Stock [Member]
Net income loss
Net proceeds					$ 200,000

Schedule of Allocation of Purch

Schedule of Allocation of Purchase Price (Details) - USD ($)	Aug. 10, 2023	Jun. 30, 2024	Dec. 31, 2023
Business Acquisition [Line Items]
Additional payments		$ 5,000,000	$ 5,000,000
Assets and liabilities acquired:
Goodwill		$ 5,878,986	$ 5,878,986
Wisconsin Fertility Institute Acquisition[Member]
Business Acquisition [Line Items]
Cash	$ 2,150,000
Holdback	350,000
Additional payments	7,500,000
Business acquisition cost	10,000,000
Assets and liabilities acquired:
FLOW intercompany receivable	528,756
Accounts receivable	214,972
Property and equipment, net	25,292
Other current assets	56,274
Goodwill	5,878,986
Deferred revenue	(389,524)
WFRSA intercompany note	(528,756)
Total assets and liabilities acquired	10,000,000
Wisconsin Fertility Institute Acquisition[Member] | Trade Names [Member]
Assets and liabilities acquired:
Noncompetition agreement	253,000
Wisconsin Fertility Institute Acquisition[Member] | Noncompete Agreements [Member]
Assets and liabilities acquired:
Noncompetition agreement	$ 3,961,000

Business Combinations (Details

Business Combinations (Details Narrative) - USD ($)	Aug. 10, 2023	Feb. 17, 2023	Feb. 03, 2023
Business Acquisition [Line Items]
Share price		$ 10.40	$ 10.40
Wisconsin Fertility Institute Acquisition[Member]
Business Acquisition [Line Items]
Purchase price	$ 10,000,000
Paid to acquire amount	2,500,000
Net payment to acquire amount	2,150,000
Payment to acquire holdback	350,000
Inter-company loan owed	$ 528,756
Wisconsin Fertility Institute Acquisition[Member] | Second Installments [Member]
Business Acquisition [Line Items]
Share price	$ 125
Wisconsin Fertility Institute Acquisition[Member] | Third Installments [Member]
Business Acquisition [Line Items]
Share price	181.80
Wisconsin Fertility Institute Acquisition[Member] | Final Installments [Member]
Business Acquisition [Line Items]
Share price	$ 285.80

Schedule of Investments in Unco

Schedule of Investments in Unconsolidated Variable Interest Entities (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Investment in unconsolidated variable interest entities	$ 844,198	$ 916,248
HRCFG INVO, LLC [Member]
Ownership percentage	50%
Investment in unconsolidated variable interest entities	$ 844,198	916,248
Positib Fertility S.A. de C.V. [Member]
Ownership percentage	33%
Investment in unconsolidated variable interest entities

Schedule of Earnings from Inves

Schedule of Earnings from Investments in Unconsolidated Variable Interest Entities (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Total earnings (loss) from unconsolidated VIEs	$ 17,846	$ 3,788	$ 17,950	$ (23,947)
HRCFG INVO, LLC [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Positib Fertility, S.A. de C.V.	17,846	19,474	17,950	805
Positib Fertility S.A. de C.V. [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Positib Fertility, S.A. de C.V.		$ (15,686)		$ (24,752)

Schedule of Financial Informati

Schedule of Financial Information of Investments in Unconsolidated Variable Interest Entities (Details) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Operating revenue	$ 1,836,597		$ 315,902		$ 3,412,883	$ 663,927
Net loss	(2,245,170)	$ (1,596,513)	(2,240,511)	$ (2,550,879)	(3,841,683)	(4,791,390)
Current assets	2,396,063				2,396,063		$ 1,259,775
Current liabilities	(7,988,798)				(7,988,798)		(8,218,875)
Variable Interest Entity, Primary Beneficiary [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Operating revenue	333,308		458,069		665,622	807,396
Operating expenses	(297,616)		(466,184)		(629,722)	(880,050)
Net loss	35,692		$ (8,115)		35,900	$ (72,654)
Current assets	286,582				286,582		288,369
Long-term assets	991,387				991,387		1,026,873
Current liabilities	(517,415)				(517,415)		(510,091)
Long-term liabilities	(123,060)				(123,060)		(123,060)
Net assets	$ 637,494				$ 637,494		$ 682,091

Variable Interest Entities (Det

Variable Interest Entities (Details Narrative) - USD ($)			3 Months Ended				6 Months Ended		12 Months Ended
	Jun. 28, 2021	Mar. 10, 2021	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Hurdle amount	$ 0
Variable interest entity ownership, percentage	150%
Net loss			$ (2,245,170)	$ (1,596,513)	$ (2,240,511)	$ (2,550,879)	$ (3,841,683)	$ (4,791,390)
Losses from equity method investments			17,846		$ 3,788		17,950	(23,947)
Georgia JV [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Investments			900,000				900,000
Notes receivable related parties			500,000				500,000
Net loss							47,000	100,000
Minority interest			0				0
Alabama JV [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Investments			1,300,000				1,300,000
Net loss							36,000	2,000
Losses from equity method investments							18,000	$ 805
Mexico JV [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Investments			$ 0				$ 0
Impairment in investment									$ 90,000
Bloom INVO LLC [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Variable interest entity commitment contribution	$ 1,200,000
Variable interest entity units issued	1,200
Bloom INVO LLC [Member] | Bloom Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Variable interest entity commitment contribution	$ 800,000
Variable interest entity units issued	800
Alabama JV [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Variable interest entity ownership, percentage		50%

Summary of Transaction with Var

Summary of Transaction with Variable Interest Entities (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Bloom INVO LLC [Member]
INVOcell revenue	$ 15,000	$ 6,000	$ 25,500	$ 10,500
Variable Interest Entity, Not Primary Beneficiary [Member]
INVOcell revenue		$ 6,750	$ 7,500	$ 9,750

Summary of Balances with Variab

Summary of Balances with Variable Interest Entities (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Notes payable	$ 2,632,988	$ 2,763,917
Bloom INVO LLC [Member]
Accounts receivable	28,500	31,500
Notes payable	489,948	482,656
Variable Interest Entity, Not Primary Beneficiary [Member]
Accounts receivable	$ 22,500	$ 15,000

Schedule of Inventory (Details)

Schedule of Inventory (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Inventory Disclosure [Abstract]
Raw materials	$ 53,480	$ 53,479
Finished goods	196,586	211,028
Total inventory	$ 250,066	$ 264,507

Schedule of Estimated Useful Li

Schedule of Estimated Useful Lives of Property and Equipment (Details)	Jun. 30, 2024
Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	3 years
Minimum [Member] | Manufacturing Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	6 years
Minimum [Member] | Medical Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	7 years
Minimum [Member] | Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	3 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	10 years
Maximum [Member] | Manufacturing Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	10 years
Maximum [Member] | Medical Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	10 years
Maximum [Member] | Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	7 years

Schedule of Property and Equipm

Schedule of Property and Equipment (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Less: accumulated depreciation	$ (282,141)	$ (233,593)
Total equipment, net	441,365	826,418
Manufacturing Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	132,513	132,513
Medical Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	404,272	303,943
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	89,904	85,404
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 96,817	$ 538,151

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 25,963	$ 19,705	$ 48,548	$ 38,792
Gain (loss) on disposal of fixed assets	$ 50,000		$ (511,663)

Schedule of Finite-Lived Intang

Schedule of Finite-Lived Intangible Assets (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Tradename	$ 253,000	$ 253,000
Noncompetition agreement	3,961,000	3,961,000
Goodwill	5,878,986	5,878,986
Less: accumulated amortization	(529,319)	(120,569)
Total intangible assets	$ 9,563,667	$ 9,972,417

Intangible Assets & Goodwill (D

Intangible Assets & Goodwill (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Aug. 10, 2023
Finite-Lived Intangible Assets [Line Items]
Goodwill	$ 5,878,986		$ 5,878,986		$ 5,878,986
Workforce value						$ 34,000
Amortization of intangible assets	$ 204,375	$ 0	$ 408,750	$ 0
Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Noncompetition agreements useful life						10 years
Noncompete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Noncompetition agreements useful life						15 years
Wisconsin Fertility Institute Acquisition[Member]
Finite-Lived Intangible Assets [Line Items]
Goodwill						$ 5,878,986
Wisconsin Fertility Institute Acquisition[Member] | Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Noncompetition agreement						253,000
Wisconsin Fertility Institute Acquisition[Member] | Noncompete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Noncompetition agreement						$ 3,961,000

Schedule of Lease Components (D

Schedule of Lease Components (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Assets
ROU assets – operating lease	$ 2,614,466	$ 5,740,929
Total ROU assets	2,614,466
Liabilities
Current operating lease liability	237,030	397,554
Long-term operating lease liability	2,506,543	$ 5,522,090
Total lease liabilities	$ 2,743,573

Schedule of Future Minimum Leas

Schedule of Future Minimum Lease Payments (Details)	Jun. 30, 2024 USD ($)
Leases
2024	$ 235,757
2025	477,947
2026	490,122
2027	480,096
2028 and beyond	2,329,321
Total future minimum lease payments	4,013,243
Less: Interest	(1,269,670)
Total operating lease liabilities	$ 2,743,573

Leases (Details Narrative)

Leases (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Leases
Weighted average remaining lease term	102 months		102 months
Weighted average discount rate	9%		9%
Operating lease payments			$ 200,000
Gain on lease termination			$ 94,551

Schedule of Notes Payable (Deta

Schedule of Notes Payable (Details) - USD ($)	Jun. 30, 2024	Jun. 28, 2024	Dec. 31, 2023
Short-Term Debt [Line Items]
Less debt discount and financing costs	$ (282,101)	$ (78,443)	$ (264,932)
Total, net of discount	2,632,988		2,763,917
Note Payable [Member]
Short-Term Debt [Line Items]
Long term debt gross	1,349,757		1,451,245
Related Party Demand Notes [Member]
Short-Term Debt [Line Items]
Long term debt gross	880,000		880,000
Convertible Notes [Member]
Short-Term Debt [Line Items]
Long term debt gross	235,000		410,000
Convertible Note One [Member]
Short-Term Debt [Line Items]
Long term debt gross	275,000
Cash Advance Agreement [Member]
Short-Term Debt [Line Items]
Long term debt gross	$ 175,332		$ 287,604

Schedule of Notes Payable (De_2

Schedule of Notes Payable (Details) (Parenthetical) - $ / shares	6 Months Ended
	Jun. 30, 2024	Dec. 31, 2023	Mar. 31, 2023
Short-Term Debt [Line Items]
Maturity date	Dec. 31, 2023
Annual interest related party demand notes percentage	10%
Annual interest related party demand conversion price			$ 12
Note Payable [Member]
Short-Term Debt [Line Items]
Maturity date	Jun. 29, 2028
Note Payable [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Annual interest related party demand notes percentage	35%
Note Payable [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Annual interest related party demand notes percentage	100%
Related Party Demand Notes [Member]
Short-Term Debt [Line Items]
Demand notes financing fee percentage	10%	10%
Annual interest related party demand notes percentage	10%	10%
Convertible Notes [Member]
Short-Term Debt [Line Items]
Annual interest related party demand notes percentage	10%	10%
Annual interest related party demand conversion price	$ 1.20	$ 1.20
Convertible Note One [Member]
Short-Term Debt [Line Items]
Annual interest related party demand notes percentage	12%	12%
Annual interest related party demand conversion price	$ 1

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)																	1 Months Ended			3 Months Ended				6 Months Ended
	Jun. 28, 2024	Apr. 05, 2024	Feb. 26, 2024	Dec. 27, 2023	Sep. 29, 2023	Aug. 31, 2023	Aug. 21, 2023	Aug. 08, 2023	Jul. 20, 2023	Jul. 10, 2023	Feb. 17, 2023	Feb. 03, 2023	Dec. 29, 2022	Dec. 13, 2022	Dec. 02, 2022	Nov. 29, 2022	Apr. 30, 2023	Mar. 31, 2023	Jan. 31, 2023	Jun. 30, 2024	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Jun. 30, 2024	Jun. 30, 2023	Apr. 17, 2024	Dec. 31, 2023
Short-Term Debt [Line Items]
Interest rate																				10%				10%
Warrant purchase of common stock, shares													17,500
Share price											$ 10.40	$ 10.40
Proceeds from convertible debt																		$ 410,000	$ 410,000				$ 200,000
Debt instrument, description																							These notes accrue 10% annual interest accrues from the date of issuance. These notes are callable with 10 days prior written notice. At maturity, the Company agreed to pay outstanding principal, a 10% financing fee, and accrued interest.
Interest expense																								$ 40,444
Conversion debt value																							$ 310,000
Debt instrument, convertible, conversion price																		$ 12				$ 12
Warrant issued																		19,375				19,375
Warrant exercise price																										$ 1.20
Maturity date																								Dec. 31, 2023
Loss from debt extinguishment	$ 40,491																			$ (40,491)				$ (40,491)
Debt discount	78,443																			282,101				282,101			$ 264,932
Debt instrument, interest rate											8%	8%
Percentage of debentures outstanding											50%	50%
Amortized of debt discount																								349,010	$ 301,098
Shares issued during period																				165,131	$ 20,297	$ 2,708,642
Number of restricted shares issued		11,655
February Purchase Agreement [Member]
Short-Term Debt [Line Items]
Purchase price											$ 450,000	$ 450,000
Proceeds from issuance											$ 2,000,000	2,000,000
Registered Direct Offering [Member]
Short-Term Debt [Line Items]
Proceeds from issuance																	$ 360,151
February Debentures [Member]
Short-Term Debt [Line Items]
Proceeds from issuance												$ 383,879
Remaining balance								$ 139,849
Cash Advance Agreement [Member]
Short-Term Debt [Line Items]
Amortized of debt discount																								139,678
Revenue Loan and Security Agreement [Member]
Short-Term Debt [Line Items]
Interest expense																								108,513
Debt discount																				12,632				12,632
Gross amount					$ 1,500,000
Amortized of debt discount																								1,579
Revenue Loan and Security Agreement [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Debt instrument, interest rate					35%
Revenue Loan and Security Agreement [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Debt instrument, interest rate					100%
Future Receipts Agreement [Member]
Short-Term Debt [Line Items]
Debt discount																				30,152				30,152
Remaining balance																				110,376				110,376
Amortized of debt discount																								89,772
Sale of shares			344,925
Purchase price of shares on sale			$ 236,250
Proceeds from sale of stock			225,000
Repayment of stock			$ 13,797
FirstFire Purchase Agreement [Member]
Short-Term Debt [Line Items]
Interest rate		12%
Interest expense																								33,000
Principal amount		$ 275,000
Amortized of debt discount																								39,539
Remaining balance of debt discount																								128,273
Shares issued during period, shares		50,000
Shares issued during period		$ 250,000
Cash fee		25,000
Interest value		$ 33,000
FirstFire Purchase Agreement [Member] | First Warrant [Member]
Short-Term Debt [Line Items]
Warrant issued		229,167
Warrant exercise price		$ 1.20
FirstFire Purchase Agreement [Member] | Second Warrant [Member]
Short-Term Debt [Line Items]
Warrant issued		500,000
Warrant exercise price		$ 0.01
Convertible Debt [Member]
Short-Term Debt [Line Items]
Interest expense																								17,766
Conversion debt value	$ 3,000,000
Warrant exercise price	$ 1.20			$ 2.25
Loss from debt extinguishment				$ 163,278
Number of warrants issued	124,421
Conversion debt																				175,000				175,000
Interest expense																				$ 22,033
Conversion debt converted to shares issued																				109,886
Common Stock [Member]
Short-Term Debt [Line Items]
Proceeds from convertible debt																		$ 135,000	$ 275,000				100,000
Debt instrument, convertible, conversion price																			$ 10
Warrant exercise price											$ 15	$ 15						$ 20				$ 20
Number of shares issued																				807,000
Proceeds from sale of stock																								200,000
Shares issued during period, shares																				260,000	115,000	69,000
Shares issued during period																				$ 26	$ 12	$ 7
Chief Executive Officer [Member]
Short-Term Debt [Line Items]
Proceeds from convertible debt														$ 25,000	$ 15,000	$ 60,000							100,000
Chief Financial Officer [Member]
Short-Term Debt [Line Items]
Proceeds from convertible debt														$ 25,000		$ 75,000							100,000
Interest expense																								$ 40,444
Related Party Demand Notes [Member]
Short-Term Debt [Line Items]
Interest rate																				10%				10%			10%
Demand notes financing fee percentage																				10%				10%			10%
Remaining balance																				$ 880,000				$ 880,000			$ 880,000
Note Warrants [Member]
Short-Term Debt [Line Items]
Warrant term																		5 years				5 years
Jan and March 2023 Convertible Notes [Member]
Short-Term Debt [Line Items]
Recoginzed amount of debt discount																								132,183
Remaining balance of debt discount																								111,044
February Debentures [Member]
Short-Term Debt [Line Items]
Interest expense																								0
Debt instrument, interest rate											105%	105%
Repayment of debt								139,849
Cash fee								$ 10,911
February Debentures [Member] | February Purchase Agreement [Member]
Short-Term Debt [Line Items]
Principal amount											$ 500,000	$ 500,000
February Warrant [Member]
Short-Term Debt [Line Items]
Warrant issued											12,500	12,500
Warrant exercise price											$ 2.85	$ 2.85
February Commitment Shares [Member]
Short-Term Debt [Line Items]
Warrant issued											4,167	4,167
February 2023 Convertible Notes [Member]
Short-Term Debt [Line Items]
Recoginzed amount of debt discount																								291,207
August Warrant[Member]
Short-Term Debt [Line Items]
Warrant exercise price								$ 2.85
February Investors [Member]
Short-Term Debt [Line Items]
Warrant issued											65,790	65,790
Number of shares issued							17,594	26,391
Shares issued during period, shares												7,500
Standard Merchant Cash Advance Agreement [Member] | Cedar [Member]
Short-Term Debt [Line Items]
Remaining balance																				64,956				64,956
Receivables purchased value						$ 746,750			$ 543,750											$ 465,000				$ 465,000
Gross purchase price									375,000
Gross amount						134,018			356,250
Repayment of debt						390,892			$ 1,941,964
Receivables purchased value						515,000
Repayments of Related Party Debt						16,594
Periodic payment						9,277
Standard Merchant Cash Advance Agreement [Member] | Cedar [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Reducation in repayment						643,750
Standard Merchant Cash Advance Agreement [Member] | Cedar [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Reducation in repayment						$ 674,650
Revenue Loan and Security Agreement [Member]
Short-Term Debt [Line Items]
Repayment of debt					$ 300,000
JAG Multi Investments LLC [Member]
Short-Term Debt [Line Items]
Proceeds from issuance of demand notes, related party										$ 100,000			$ 100,000										$ 500,000
Warrant term													5 years										5 years
Share price													$ 10
Debt instrument, description																							These notes are callable with 10 days prior written notice. At maturity, the Company agreed to pay outstanding principal, a 10% financing fee, and accrued interest.
Principal amount										$ 110,000													$ 220,000
JAG Multi Investments LLC [Member] | Related Party Demand Notes [Member]
Short-Term Debt [Line Items]
Proceeds from issuance of demand notes, related party																							$ 550,000

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)

1 Months Ended

3 Months Ended

6 Months Ended

Jul. 10, 2023

Dec. 29, 2022

Dec. 13, 2022

Dec. 02, 2022

Nov. 29, 2022

Mar. 31, 2023

Jan. 31, 2023

Dec. 31, 2022

Jun. 30, 2024

Dec. 31, 2023

Feb. 17, 2023

Feb. 03, 2023

Related Party Transaction [Line Items]

Annual interest related party demand notes percentage

10%

Warrant purchase of common stock, shares

17,500

Share price

$ 10.40

$ 10.40

Proceeds from convertible debt

$ 410,000

$ 410,000

$ 200,000

Debt instrument, description

These notes accrue 10% annual interest accrues from the date of issuance. These notes are callable with 10 days prior written notice. At maturity, the Company agreed to pay outstanding principal, a 10% financing fee, and accrued interest.

Interest costs incurred

$ 40,444

Accrued compensation

375,422

Chief Executive Officer [Member]

Related Party Transaction [Line Items]

Proceeds from convertible debt

$ 25,000

$ 15,000

$ 60,000

$ 100,000

Chief Financial Officer [Member]

Related Party Transaction [Line Items]

Proceeds from convertible debt

$ 25,000

$ 75,000

100,000

Interest costs incurred

40,444

JAC MultiInvestments LLC [Member]

Related Party Transaction [Line Items]

Principal amount

500,000

JAG Multi Investments LLC [Member]

Related Party Transaction [Line Items]

Gross purchase price

200,000

Related Party [Member]

Related Party Transaction [Line Items]

Accounts payable related parties

$ 227,321

Related Party Demand Notes [Member]

Related Party Transaction [Line Items]

Annual interest related party demand notes percentage

10%

10%

Demand notes financing fee percentage

10%

10%

JAG Multi Investments LLC [Member]

Related Party Transaction [Line Items]

Proceeds from issuance of demand notes, related party

$ 100,000

$ 100,000

500,000

Principal amount

$ 110,000

$ 220,000

Warrants exercises term

5 years

5 years

Share price

$ 10

Debt instrument, description

These notes are callable with 10 days prior written notice. At maturity, the Company agreed to pay outstanding principal, a 10% financing fee, and accrued interest.

JAG Multi Investments LLC [Member] | Related Party Demand Notes [Member]

Related Party Transaction [Line Items]

Proceeds from issuance of demand notes, related party

$ 550,000

Schedule of Closing Price for N

Schedule of Closing Price for NAYA's Purchases of Remaining Shares (Details) - NAYA Biosciences Merger [Member] - Securities Purchase Agreement [Member] - USD ($)										6 Months Ended
	Jul. 05, 2024	Jun. 28, 2024	Jun. 21, 2024	Jun. 14, 2024	Jun. 07, 2024	May 31, 2024	May 24, 2024	May 17, 2024	May 10, 2024	Jun. 30, 2024
Restructuring Cost and Reserve [Line Items]
Shares	30,000	30,000	30,000	30,000	30,000	30,000	30,000	30,000	20,000	598,800
Aggregate Purchase Price	$ 150,000	$ 150,000	$ 150,000	$ 150,000	$ 150,000	$ 150,000	$ 150,000	$ 150,000	$ 100,000	$ 2,894,000

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)																																		1 Months Ended		3 Months Ended				6 Months Ended
	Jul. 05, 2024	Jun. 30, 2024	Jun. 28, 2024	Jun. 21, 2024	Jun. 14, 2024	Jun. 07, 2024	May 31, 2024	May 24, 2024	May 17, 2024	May 10, 2024	May 01, 2024	Apr. 16, 2024	Apr. 15, 2024	Apr. 05, 2024	Mar. 27, 2024	Feb. 16, 2024	Feb. 02, 2024	Jan. 31, 2024	Jan. 19, 2024	Jan. 04, 2024	Dec. 29, 2023	Dec. 27, 2023	Nov. 20, 2023	Nov. 19, 2023	Aug. 21, 2023	Aug. 10, 2023	Aug. 08, 2023	Aug. 04, 2023	Jul. 26, 2023	Jul. 07, 2023	Mar. 27, 2023	Mar. 23, 2023	Feb. 03, 2023	Apr. 30, 2024	Aug. 31, 2023	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023	Apr. 17, 2024	Dec. 31, 2023	Oct. 22, 2023	Oct. 13, 2023	Oct. 12, 2023	Jun. 28, 2023	Jun. 27, 2023	Feb. 17, 2023	Jan. 31, 2023	Dec. 29, 2022
Common stock, shares authorized		50,000,000																																		50,000,000				50,000,000			50,000,000		50,000,000	6,250,000
Preferred Stock, Par or Stated Value Per Share		$ 5																																		$ 5				$ 5
Debt Instrument, Convertible, Conversion Price																																							$ 12
Gross proceeds																																				$ 165,131		$ 20,297	$ 2,708,642
Number of shares issued private offering value																																								$ 1,506,404
Number of warrants issued																																							19,375
Exercise price																																										$ 1.20
Additional gross proceeds from warrants exercises																																								900,611
Proceeds from sale of common stock																																								$ 165,131	$ 2,728,938
Number of warrant purchase, shares																																																			17,500
Common stock, par value		$ 0.0001																																		$ 0.0001				$ 0.0001			$ 0.0001
Stock issued during for services, value																																				$ 59,998	$ 142,450	$ 94,276	$ 149,900
Exercise warrants to purchase shares
Exercised warrants issued, value																																							$ 2,376
Common Stock [Member]
Warrants to purchase shares																																				260,000		115,000	69,000
Debt Instrument, Convertible, Conversion Price																																																		$ 10
Gross proceeds																																				$ 26		$ 12	$ 7
Exercise price																																	$ 15						$ 20										$ 15
Purchase warrants exercisable																																				807,000
Proceeds from issuance or sale of equity																																								$ 200,000
Stock issued during for services																																				69,155	125,500	12,817	13,000
Stock issued during for services, value																																				$ 6	$ 13	$ 2	$ 1
Exercise warrants to purchase shares																																							297
Exercised warrants issued, value
February Investors [Member]
Warrants to purchase shares																																	7,500
Number of warrants issued																																	65,790																65,790
Purchase warrants exercisable																									17,594		26,391
February Debentures [Member]
Repayments of debt																											$ 139,849
Fee amount																											10,911
NAYA Biosciences Merger [Member]
Preferred Stock, Par or Stated Value Per Share																						$ 5																						$ 5
Common stock, par value																																												$ 0.0001
Purchase agreement, description																						The parties further agreed to the following schedule (the “Minimum Interim PIPE Schedule”) for the initial $2,000,000: (1) $500,000 no later than December 29, 2023, (2) $500,000 no later than January 19, 2024, (3) $500,000 no later than February 2, 2024, and (4) $500,000 no later than February 16, 2024.
Securities Purchase Agreement [Member]
Warrants to purchase shares		140,080											61,200					100,000
Shares issued price per share																																$ 12.60
Gross proceeds		$ 700,404											$ 306,000					$ 500,000
Number of warrants issued																																115,000
Exercise price																														$ 2.85		$ 0.20
Purchase warrants exercisable																																276,000
Amendment fee																														$ 1,000,000
Stock issued during for services																																69,000
Securities Purchase Agreement [Member] | Public Offering [Member]
Warrants to purchase shares																												1,580,000
Number of warrants issued																												3,160,000
Exercise price																												$ 2.85
Sale of stock																												1,580,000
Share price																												$ 2.85
Securities Purchase Agreement [Member] | NAYA Biosciences Merger [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	30,000		30,000	30,000	30,000	30,000	30,000	30,000	30,000	20,000																														598,800
Share Exchange Agreement [Member]
Warrants to purchase shares																								1,200,000
Equity Purchase Agreement [Member]
Proceeds from sale of shares																																	$ 10,000,000
Purchase of shares of common stock description																																	(i) in a minimum amount of not less than $25,000 and (ii) in a maximum amount of up to the lesser of (a) $750,000 or (b) 200% of the Company’s average daily trading value of the common stock.
March Purchase Agreement [Member]
Warrants to purchase shares																																69,000
Shares issued price per share																																$ 12.60
Number of warrants issued																																115,000
Exercise price																																$ 0.20
Purchase warrants exercisable																																276,000
Proceeds from issuance initial public offering																															$ 3,000,000
Additional gross proceeds from warrants exercises																															$ 3,500,000
February Debentures [Member]
Proceeds from issuance of debt																																	$ 383,879
Purchase Agreements [Member] | Public Offering [Member]
Warrants to purchase shares																												1,580,000
Number of warrants issued																												3,160,000
Exercise price																												$ 2.85
Sale of stock																												1,580,000
Share price																												$ 2.85
Proceeds from sale of common stock																												$ 4,500,000
Proceeds from issuance or sale of equity																											2,150,000
Purchase price																										$ 350,000
Amendment fee																											$ 1,000,000
Placement Agency Agreement [Member] | Maxim Group LLC [Member]
Exercise price																												$ 3.14
Percentage of pay placement agent aggregate fee																												7%
Percentage of investors																												5%
Number of warrant purchase, shares																												110,600
Securities Purchase Agreements [Member]
Shares issued price per share																																			$ 2.85
Armistice fee																																			$ 1,000,000
Triton Purchase Agreement [Member]
Warrants to purchase shares														75,000																				260,000
Shares issued price per share															$ 0.85
Gross proceeds															$ 850,000
Proceeds from sale of common stock														$ 10,131																				$ 165,131
Common stock, par value															$ 0.0001
Purchase agreement, description															The Triton Purchase Agreement expires upon the earlier of the sale of all 1,000,000 shares of the Company’s common stock or December 31, 2024.
Proceeds from sale of common stock															260,000
Stock return, shares														185,000
Conversion of period shares																																		109,886
Conversion of period value																																		$ 197,033
Triton Purchase Agreement [Member] | Common Stock [Member]
Proceeds from sale of common stock												$ 155,000
Proceeds from sale of common stock												185,000
Triton Purchase Agreement [Member] | August 2023 Warrants [Member]
Exercise warrants to purchase shares																																		807,000
Exercised warrants issued, value																																		$ 971,012
Triton Purchase Agreement [Member] | Maximum [Member]
Warrants to purchase shares															1,000,000
Series A Preferred Stock [Member]
Warrants to purchase shares																							1,000,000
Shares issued price per share																							$ 5
Preferred Stock, Par or Stated Value Per Share		$ 5																					5													$ 5				$ 5			5
Debt Instrument, Convertible, Conversion Price																							$ 2.20
Preferred Stock, Convertible, Terms																							The Company may not effect the conversion of any shares of Series A Preferred if, after giving effect to the conversion or issuance, the holder, together with its affiliates, would beneficially own more than 9.99% of the Company’s outstanding common stock. Moreover, the Company may not effect the conversion of any shares of Series A Preferred if, after giving effect to the conversion or issuance, the holder, together with its affiliates, would beneficially own more than 19.99% of the Company’s outstanding common stock unless and until the Company receives the approval required by the applicable rules and regulations of The Nasdaq Stock Market LLC (or any subsequent trading market).
Series A Preferred Stock [Member] | Securities Purchase Agreement [Member]
Warrants to purchase shares																				100,000	1,000,000															201,280
Shares issued price per share																					$ 5
Number of shares issued private offering value																				$ 500,000																$ 1,006,400
Series A Preferred Stock [Member] | Securities Purchase Agreement [Member] | NAYA Biosciences Merger [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares											838,800
Purchase price per share											$ 5
Series A Preferred Stock [Member] | Securities Purchase Agreement [Member] | Share-Based Payment Arrangement, Tranche One [Member]
Gross proceeds																					$ 500,000
Series A Preferred Stock [Member] | Securities Purchase Agreement [Member] | Share-Based Payment Arrangement, Tranche Two [Member]
Gross proceeds																			$ 500,000
Series A Preferred Stock [Member] | Securities Purchase Agreement [Member] | Share-Based Payment Arrangement, Tranche Three [Member]
Gross proceeds																	$ 500,000
Series A Preferred Stock [Member] | Securities Purchase Agreement [Member] | Share Based Compensation Award Tranche Four [Member]
Gross proceeds																$ 500,000
Series B Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share		$ 5																																		$ 5				$ 5			$ 5
Series B Preferred Stock [Member] | Securities Purchase Agreement [Member]
Warrants to purchase shares																							1,200,000
Shares issued price per share																							$ 5
Series B Preferred Stock [Member] | Securities Purchase Agreement [Member] | Nonconsolidated Investees, Other [Member]
Beneficially percentage																							19.99%
Series B Preferred Stock [Member] | Share Exchange Agreement [Member]
Warrants to purchase shares																								163,637
Series B Preferred Stock [Member] | Share Exchange Agreement [Member] | Nonconsolidated Investees, Other [Member]
Beneficially percentage																							6.50%
Board of Directors [Member]
Common stock, shares authorized																																															6,250,000	125,000,000
Reverse stock split																													the Company filed a certificate of change (with an effective date of July 28, 2023) with the Nevada Secretary of State pursuant to Nevada Revised Statutes 78.209 to effectuate a 1-for-20 reverse stock split of its outstanding common stock
Consultant [Member]
Stock issued during for services																																								194,655
Stock issued during for services, value																																								$ 202,448

Schedule of Stock Options Activ

Schedule of Stock Options Activity (Details)	6 Months Ended
	Jun. 30, 2024 USD ($) $ / shares shares
Equity [Abstract]
Number of shares, options outstanding | shares	106,753
Weighted average exercise price, outstanding	$ 41.90
Aggregate intrinsic value, outstanding | $
Number of shares, options outstanding, granted | shares
Weighted average exercise price, options outstanding, granted
Aggregate intrinsic value, granted | $
Number of shares, options outstanding, exercised | shares
Weighted average exercise price, options outstanding, exercised
Aggregate intrinsic value, exercised | $
Number of shares, options outstanding, canceled | shares	(8,761)
Weighted average exercise price, outstanding, canceled	$ 31.58
Aggregate intrinsic value, canceled
Number of shares, options outstanding | shares	97,992
Weighted average exercise price, outstanding	$ 35.20
Aggregate intrinsic value, outstanding | $
Number of shares, options exercisable | shares	88,218
Weighted average exercise price, options exercisable	$ 51.67
Aggregate intrinsic value, options exercisable | $

Schedule of Share-Based Payment

Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions (Details)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Risk-free interest rate range
Risk-free interest rate range, minimum		3.60%
Risk-free interest rate range, maximum		3.69%
Expected stock price volatility
Expected stock price volatility, minimum		106.60%
Expected stock price volatility, maximum		114.90%
Expected dividend yield
Minimum [Member]
Expected life of option-years		5 years
Maximum [Member]
Expected life of option-years		5 years 7 months 17 days

Schedule of Share Based Payment

Schedule of Share Based Payments Arrangements Options Exercised and Options Vested (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Equity [Abstract]
Total intrinsic value of options exercised
Total fair value of options vested	$ 140,336	$ 1,049,109

Schedule of Aggregate Restricte

Schedule of Aggregate Restricted Stock Awards and Restricted Stock Unit Activity (Details) - Restricted Stock [Member] - 2019 Stock Incentive Plan [Member]	6 Months Ended
	Jun. 30, 2024 USD ($) $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of unvested shares, balance | shares	25
Weighted averag exercise price, balance | $ / shares	$ 18.42
Aggregate value of unvested shares, balance | $	$ 5,525
Number of unvested shares, granted | shares
Weighted average exercise price, granted | $ / shares
Aggregate value of unvested shares, granted | $
Number of unvested shares, vested | shares
Weighted average exercise price, vested | $ / shares
Aggregate value of unvested shares, vested | $
Number of unvested shares, forfeitures | shares
Weighted average exercise price, forfeitures | $ / shares
Aggregate value of unvested shares, forfeitures | $
Number of unvested shares, balance | shares	25
Weighted averag exercise price, balance | $ / shares	$ 18.42
Aggregate value of unvested shares, balance | $	$ 5,525

Equity-Based Compensation (Deta

Equity-Based Compensation (Details Narrative) - USD ($)		6 Months Ended	12 Months Ended
	Apr. 05, 2024	Jun. 30, 2024	Dec. 31, 2023	Jan. 31, 2024	Oct. 31, 2019
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vested in period fair value		$ 140,336	$ 1,049,109
Restricted stock shares, gross	11,655
Share-Based Payment Arrangement [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted average remaining service period		1 year
Restricted Stock [Member] | Employees, Directors and Consultants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Restricted stock shares, gross		0
Share based compensation vesting period		1 year
2019 Stock Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based compensation, number of shares authorized				311,049	25,000
Share-based compensation, description		A provision in the 2019 Plan provides for an automatic annual increase equal to 6% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year.
Share-based compensation number of shares, grant				149,551
Vested in period fair value		$ 140,336
2019 Stock Incentive Plan [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Option life		3 years
2019 Stock Incentive Plan [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Option life		10 years

Schedule of Unit Purchase Optio

Schedule of Unit Purchase Option Activity (Details)	6 Months Ended
	Jun. 30, 2024 USD ($) $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares, options outstanding | shares	106,753
Weighted average exercise price, outstanding	$ 41.90
Aggregate intrinsic value, outstanding | $
Number of unit purchase options, granted | shares
Weighted average exercise price, granted
Number of unit purchase options, exercised | shares
Weighted average exercise price, exercised
Aggregate intrinsic value, exercised | $
Number of unit purchase options, canceled | shares	8,761
Weighted average exercise price, canceled	$ 31.58
Aggregate intrinsic value, canceled
Number of shares, options outstanding | shares	97,992
Weighted average exercise price, outstanding	$ 35.20
Aggregate intrinsic value, outstanding | $
Unit Purchase Options [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares, options outstanding | shares	4,649
Weighted average exercise price, outstanding	$ 64
Aggregate intrinsic value, outstanding | $
Number of unit purchase options, granted | shares
Weighted average exercise price, granted
Aggregate intrinsic value, granted
Number of unit purchase options, exercised | shares
Weighted average exercise price, exercised
Aggregate intrinsic value, exercised | $
Number of unit purchase options, canceled | shares
Weighted average exercise price, canceled
Aggregate intrinsic value, canceled
Number of shares, options outstanding | shares	4,649
Weighted average exercise price, outstanding	$ 64
Aggregate intrinsic value, outstanding | $

Schedule of Warrants Activity (

Schedule of Warrants Activity (Details)	6 Months Ended
	Jun. 30, 2024 USD ($) $ / shares shares
Unit Purchase Options And Warrants
Number of warrants, outstanding | shares	3,488,620
Weighted average exercise price, outstanding | $ / shares	$ 3.95
Aggregate intrinsic value, outstanding | $
Number of warrants, granted | shares	1,444,812
Weighted average exercise price, granted | $ / shares	$ 1.80
Aggregate intrinsic value, granted | $
Number of warrants, exercised | shares	(807,000)
Weighted average exercise price, exercised | $ / shares	$ 1.20
Aggregate intrinsic value, exercised | $
Number of warrants, canceled | shares
Weighted average exercise price, canceled | $ / shares
Aggregate intrinsic value, canceled | $
Number of warrants, outstanding | shares	4,126,432
Weighted average exercise price, outstanding | $ / shares	$ 1.79
Aggregate intrinsic value, outstanding | $

Unit Purchase Options and War_3

Unit Purchase Options and Warrants (Details Narrative) - USD ($)														1 Months Ended	3 Months Ended			6 Months Ended
	Jun. 30, 2024	Jun. 28, 2024	Apr. 17, 2024	Apr. 15, 2024	Apr. 05, 2024	Mar. 27, 2024	Jan. 31, 2024	Dec. 27, 2023	Aug. 21, 2023	Aug. 08, 2023	Aug. 04, 2023	Jul. 07, 2023	Mar. 23, 2023	Apr. 30, 2024	Jun. 30, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023	Apr. 16, 2024	Feb. 17, 2023	Feb. 03, 2023	Jan. 31, 2023	Dec. 29, 2022
Warrant issued																	19,375
Exercise price			$ 1.20
Loss from debt extinguishment		$ (40,491)													$ 40,491			$ 40,491
Warrants to purchase																								17,500
Proceeds from exercise of warrants																		900,611
Proceeds from the sale of common stock, net of fees and expenses															$ 165,131	$ 20,297	$ 2,708,642
Stock Issued During Period, Shares, Restricted Stock Award, Gross					11,655
Securities Purchase Agreement [Member]
Warrant issued													115,000
Exercise price												$ 2.85	$ 0.20
Common stock issued													69,000
Warrant exercise, shares													276,000
Exercise price													$ 12.60
Amendment fee												$ 1,000,000
Proceeds from the sale of common stock, net of fees and expenses, shares	140,080			61,200			100,000
Proceeds from the sale of common stock, net of fees and expenses	$ 700,404			$ 306,000			$ 500,000
Securities Purchase Agreement [Member] | Public Offering [Member]
Warrant issued											3,160,000
Exercise price											$ 2.85
Sale of stock											1,580,000
Share price											$ 2.85
Proceeds from the sale of common stock, net of fees and expenses, shares											1,580,000
Placement Agency Agreement [Member] | Maxim Group LLC [Member]
Exercise price											$ 3.14
Warrants to purchase											110,600
Triton Purchase Agreement [Member]
Exercise price						$ 0.85
Proceeds from the sale of common stock, net of fees and expenses, shares					75,000									260,000
Proceeds from the sale of common stock, net of fees and expenses						$ 850,000
Triton Purchase Agreement [Member] | Warrant [Member]
Warrant issued						1,000,000
Exercise price						$ 2
Stock based compensation						$ 971,012
FirstFire Purchase Agreement [Member]
Proceeds from the sale of common stock, net of fees and expenses, shares					50,000
Proceeds from the sale of common stock, net of fees and expenses					$ 250,000
Debt Instrument, Fee Amount					$ 25,000
First Warrant [Member] | FirstFire Purchase Agreement [Member]
Warrant issued					229,167
Exercise price					$ 1.20
Second Warrant [Member] | FirstFire Purchase Agreement [Member]
Warrant issued					500,000
Exercise price					$ 0.01
Convertible Notes [Member]
Warrants issued term																	5 years						5 years
Warrant issued																	19,375						19,375
Exercise price																	$ 20			$ 2.85			$ 20
Warrant exercise price decrease								$ 2.25
Loss from debt extinguishment																		$ 163,278
Warrant exercise, shares														807,000
Proceeds from exercise of warrants			$ 250,635											$ 968,400
Convertible Debentures [Member]
Warrant issued																					12,500	12,500
Exercise price																					$ 15	$ 15
Purchase price																					$ 2.85	$ 2.85
Common stock issued									17,594	26,391
Convertible Debentures [Member] | February Warrants [Member]
Warrant issued																					65,790	65,790
Exercise price																					$ 2.85	$ 2.85

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Income tax expense		$ 2,865	$ 1,836	$ 2,865
Income tax rate			0%

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	Dec. 27, 2023	Oct. 22, 2023	Jun. 30, 2024	Dec. 31, 2023
Loss Contingencies [Line Items]
Common stock, par value			$ 0.0001	$ 0.0001
Preferred stock, par value			$ 5
NAYA Biosciences Merger [Member]
Loss Contingencies [Line Items]
Common stock, par value		$ 0.0001
Converted shares to receive		7.33333
Common stock estimated amount		$ 5,000,000
Preferred stock, par value	$ 5	$ 5
Liabilities		$ 5,000,000
Common stock at a target price		$ 5
Termination fee		$ 1,000,000
Common stock in an estimated amount	$ 5,000,000
Purchase agreement description	The parties further agreed to the following schedule (the “Minimum Interim PIPE Schedule”) for the initial $2,000,000: (1) $500,000 no later than December 29, 2023, (2) $500,000 no later than January 19, 2024, (3) $500,000 no later than February 2, 2024, and (4) $500,000 no later than February 16, 2024.
Payment to puchse preferred stock	$ 1,506,404
NAYA Biosciences Merger [Member] | Merger Agreement [Member]
Loss Contingencies [Line Items]
Termination fee		1,000,000
NAYA Biosciences Merger [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Liabilities		$ 5,000,000
NAYA Biosciences Merger [Member] | Common Class A [Member]
Loss Contingencies [Line Items]
Common stock, par value		$ 0.000001
NAYA Biosciences Merger [Member] | Common Class B [Member]
Loss Contingencies [Line Items]
Number of shares issued for acquisitions		18,150,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - Common Stock [Member] - shares	1 Months Ended	3 Months Ended
	Aug. 31, 2024	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023
Subsequent Event [Line Items]
Common stock issued for services, shares		69,155	125,500	12,817	13,000
Subsequent Event [Member] | Consultants [Member]
Subsequent Event [Line Items]
Common stock issued for services, shares	42,000